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Abstract approved:
Reported here is an investigation to determine if azinphos-methyl (AZM), an
organophosphate insecticide, adducts to hemoglobin, and if so, whether the
hemoglobin adduct could be used as a quantitative marker of occupational AZM
exposure. We hypothesized that AZM, or a metabolite of AZM,binds to hemoglobin
in erythrocytes forming an adducted protein. We administered radiolabled AZM to
rats and found a stable, dose-dependent association of radioactivity with hemoglobin.
The decline in hemoglobin-associated radioactivity followed the expected kinetics of
erythrocyte turnover in rats. We examined hemoglobin isolated from these rats by
high-pressure liquid chromatography, liquid scintillation counting, and electrospray
ionization mass spectrometry. These analyses provided evidence of AZM or an AZM
metabolite binding to one of the beta proteins of hemoglobin. In vitro incubation of
AZM with hemoglobin in a liver microsome system indicated an AZM adduct to
heme. Further research is necessary to fully characterize the adduct and determine
whether this biomarker will be useful for monitoring human exposure to AZM.
Redacted for Privacy' Copyrig ht by Bonnie J. Bailey
May 5, 2000
All Rights ReservedHemoglobin Adducts of the Organophosphate Insecticide Azinphos-methyl
by
Bonnie J. Bailey
A DISSERTATION
submitted to
Oregon State University
in partial fulfillment of
the requirements for the
degree of
Doctor of Philosophy
Presented May 5, 2000
Commencement June 2000Doctor of Philosophy dissertation of Bonnie J. Bailey presented on May 5, 2000
APPROVED:
Major Professor, represen
Chair of Department of Environmental and Molecular Toxicology
Dean of Gradechool
I understand that my dissertation will become part of the permanent collection of
Oregon State University libraries. My signature below authorizes release of my
dissertation to any reader upon request.
Bahnie J. Bailey,uthor
Redacted for Privacy
Redacted for Privacy
Redacted for Privacy
Redacted for PrivacyACKNOWLEDGEMENTS
I would never have completed graduate school without the help of many people. I
thank Don Armstrong (one of my undergraduate professors) who encouraged me to
attend graduate school. I thank the members of my committee: Jeff Jenkins, Max
Deinzer, Sheldon Wagner, Nancy Kerkvliet, and Jerry Heidel for their assistance. I
thank Don Buhler for use of laboratory space and equipment. I thank Max Deinzer for
use of the mass spectrometry facilities and for many hours of input on my researchand
dissertation. I thank Don Griffin and Claudia Maier for assistance with mass
spectrometry. I thank Pat Thomson and Wanda Parrot for being my surrogate mothers
and for their professional expertise as chemical information specialist and editor,
respectively. I thank Marilyn Henderson for research assistance above and beyond the
call of duty. I thank Sam Ebbert my office mate, friend, and cage cleaner par
exellence. I thank Margaret Pratt for help preparing some of the figures. I thank the
National Institute of Environmental Health Sciences for financial support. I thank
Bayer Corporation for providing radiolabled azinphos-methyl. I thank CH2M Hill for
allowing me time off from work to write my dissertation. I thank my friends and
family for their support and encouragement.TABLE OF CONTENTS
Page
1. Introduction 1
2. Association of Azinphos-methyl with Rat Erythrocytes and Hemoglobin 30
3. Analysis of Rat Hemoglobin Exposed to [14C]Azinphos-methyl In Vivo 49
4.Evidence for a Heme Adduct Generated by In Vitro Incubation of Azinphos-
methyl with Rat Hemoglobin in a Liver Microsome System 71
5. Summary 87
6. Summary for Non-scientists 91
7. Statement of Educational Philosophy 94
Bibliography 97LIST OF FIGURES
Figure Page
1.1 Molecular structure of azinphos-methyl 3
1.2 Metabolic scheme of azinphos-methyl in rats 8
1.3 Reactions of acetylcholine and azinphos-methyl with acetylcholinesterase 10
1.4 ESI/MS of the alpha2 globin of rat hemoglobin 28
2.1 Dose-response of [14C]AZM with erythrocytes 3 days post-exposure 41
2.2 Dose-response of [14C]AZM with hemoglobin 3 days post-exposure 41
2.3 Stability of [14C]AZM associated with erythrocytes 43
2.4 Stability of [14C]AZM associated with hemoglobin 44
2.5 Comparison of observed adduct removal in rats receiving a single dose of
3 mg/kg [14C]AZM with the modeled results 44
3.1 Radioactivity in whole blood shows dose dependent association of
radioactivity 63
3.2 (a) Radioactivity in hemoglobin HPLC fractions. (b) HPLC chromatogram of
hemoglobin 66
4.1 Herne adduct (mw = 933.2) present in sample containing hemoglobin, active
microsome system, and AZM 78
4.2 Heme adduct (mw = 933.2) present in sample without active microsome system
with hemoglobin and AZM 79
4.3 Heme adduct absent from sample without AZM, with hemoglobin and active
microsome system 80
4.4 Molecular structure of heme 81LIST OF TABLES
Table Page
1.1 Summary of Hemoglobin Adduct Analytical Methods 26
2.1 Average AChE activity 3 days after treatment 42
2.2 Average AChE activity after treatment with 3 mg/kg [14C]AZM 42
2.3 [14C]AZM binding efficiency with erythrocytes and hemoglobin 47
3.1 Summary of rat plasma cholinesterase following treatment with [14C]AZM61
3.2 Summary of rat brain cholinesterase 7 days post-exposure following treatment
with [14C]AZM 62
3.3 Covalent binding analyis of hemoglobin from [14C]AZM treated rats 64
3.4 Summary of HPLC/fraction collection/LSC of hemoglobin 65
4.1 Hemoglobin AZM microsomal incubation/ESI-MS 77
4.2 Hemoglobin AZM microsome incubation conditions 82DEDICATION
My dissertation is dedicated to the teachers who inspired and encouraged me.Hemoglobin Adducts of the Organophosphate Insecticide Azinphos-methyl
Chapter 1
Introduction
Problem statement:
In this study we intended to determine if azinphos-methyl (AZM), an
organophosphate insecticide, adducts to hemoglobin and if so, whether this adducted
hemoglobin could be used as a quantitative marker of occupational AZM exposure.
We hypothesized that AZM or a metabolite of AZM binds to hemoglobin in
erythrocytes forming an adducted protein.
Rational:
1.Researchers reported that 16 days after rats were treated with carbonyl-14C-
labelled AZM the total amount of radioactivity in the body had declined to
1% of administered activity, but the highest concentration was found in the
erythrocytes. When these researchers incubated whole blood with labeled
AZM, there was no accumulation of radioactivity in the erythrocytes
(Watson, 1992).
2.Metabolites of AZM contain functional groups that could react with
hemoglobin, resulting in a covalently bound adduct. Mercaptomethyl-
benzazamide is a P450 mediated AZM metabolite that contains a free
sulhydryl group (Watson, 1992). Sulfhydryl groups have been found to2
form disulfide bonds with free cysteine residues in hemoglobin (Schnell,
1994). Several other AZM metabolites contain a thiol group, which can
bind to cysteine residues by the action of GSH transferase (Watson, 1992).
General AZM Information
AZM was first produced in 1953 by Farbenfabriken Bayer AG. It is manufactured
in the US under the tradename Guthion. AZM is used to control insects of the orders
Coleoptera, Diptera, and Homoptera. AZM is commonly used in U.S. agriculture on a
variety of crops including cotton, apples, pears, sugar cane, cranberries, strawberries,
potatoes, cereals, corn, soy beans, tobacco, rice, ornamentals, and shrubs. Each year,
growers apply more than 1 million pounds of AZM to crops (Schreiber, 1997)
AZM (CAS number 86-50-0) has a molecular weight of 317.3, a melting point of
73 °C, a vapor pressure of 5 x 104 mPa (20 °C), a Kow logP = 2.96, and a Henry's
Law constant of 5.7 x 10'6 Pa m3 mol'i (20 °C, calc). It has a water solubility of 28
mg/L (20 °C). It is soluble in dichloroethane, acetone, acetonitrile, ethyl acetate,
dimethyl sulfoxide >250, n-heptane 1.2, xylene 170 (all in g/L, 20 °C). AZM is rapidly
hydrolyzed in alkaline and acidic conditions (Tomlin, 1997). The molecular structure
of AZM is shown in Fig. 1.13
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Fig. 1.1 Molecular structure of azinphos-methyl
AZM is only used in agriculture; therefore, agricultural workers are the main
population of concern. Agricultural laborers who handle AZM or work in treated
fields are exposed to AZM (Drevenkar et al., 1991; McCurdy et al., 1994). The
primary routes of exposure for agricultural laborers varies somewhat depending on the
tasks performed, but dermal absorption and hand-to-mouth contact are the most
significant (Jegier et al., 1964; Aprea et al., 1994; Moate, 1996)
There has been increasing pressure from the US Environmental Protection Agency
(EPA) and environmental groups to reduce the use of organophosphate (OPs)
pesticides especially since the passage of the Food Quality Protection Act (FQPA)
enacted by U.S. Congress in August 1996. The FQPA changed the way pesticides are
regulated in the U.S. AZM was one of the first OPs reviewed under the FQPA. There
is continuing debate between the pesticide manufacturers, EPA, and academic
scientists about the level of risk posed to agricultural workers.4
History of OPs
Although the first organophosphorus ester tetraethylpyrophosphate (TEPP) was
synthesized by the organic chemist Clermont in 1854, the potential for mammalian
effects of these esters was not recognized until the 1932 synthesis of
diethylfluorophosphate (DEFP), now considered the ancestor of all toxic OP
compounds. Reports of very small amounts of DEFP vapor producing laryngeal
pressure, breathlessness, cloudiness of vision and painful light sensitivity of the eyes
led the German scientist Schrader to explore this class of compounds for insecticidal
activities. The German government declared all research on OP compounds secret in
1938. Research was divided into insecticidal and homicidal chemical warfare
branches, one to synthesize chemicals less acutely toxic to man for use as insecticides,
the other to develop compounds more acutely toxic, more volatile, and less persistent
for use as nerve gases or poison gas (such as Sarin, soman, and tabun). TEPP was
"rediscovered" to have insecticidal properties and was marketed in Germany in 1944
as Bladan. Similiar work in the U.S. and Britain during WWII resulted in the synthesis
of the OP diisopropylphosphorofluoridate (DFP), the demonstration of the OP
inhibition of the neurotransmitter acetylcholinesterase, and later its use in the medical
treatment of glaucoma (Chambers, 1992a; Ware, 1994; Gallo and Lawryk, 1991).
Numerous other OP insecticides have been developed for commercial use since
WWII.5
Chemical Strucutures of OPs
Of the three principal groups of insecticides, organophosphates, chlorinated
hydrocarbons and carbamates, the OPs form the largest group by far. Also referred to
as OP esters, the general formula for these compounds is P X, in which X is the
leaving group. The central portion common to all OPs is phosphonic acid P - OH,
which when reacted with water forms an ester. The X constituent places the compound
in 1 of 4 main categories: I. X contains a quaternary nitrogen; II. X = F; III. X = CN,
OCN, SCN, or halogen other than F; IV. contains at least 8 subgroups depending on
R1 and R2, (alkyl; alkoxy or alkylthio; aryl or one of their heterocyclic analogs;
aryloxy, arylthio or one of their heterocyclic analogs; nitrogen; or disubstituted
phosphoryl groups), with the R groups identical in subgroups 1-7 (Chambers, 1992a;
Gallo and Lawryk, 1991).
Commercial insecticide compounds are of three main groups: phosphates, without
a S atom; phosphorothioates, with one S atom; and phosphorodithioates, with two S
atoms. AZM is a phosphorothioate. Since the P=S form is intrinsically more stable,
many insecticides (including AZM) are manufactured in this form, which can be
converted to the biologically active oxon (P=0).
AZM Absorption, Distribution and Excretion
Carbonyl -14C- labelled AZM orally administered to rats was almost completely
absorbed from the digestive tract (Watson, 1992). Sixty to seventy percent was6
eliminated in the urine and 25-35% in the feces within 48 hours. Radioactivity in
blood from 32P-labelled AZM administered in the diet of cows peaked 4-6 hours after
administration, declining sharply over the next 30 hours, then declining gradually to
the last sample collection time, at 72 hours post-exposure. The pattern of radioactivity
in the urine closely paralleled the pattern in the blood. Radioactivity in the milk
peaked at 24 hours, remained relatively high through 48 hours, then gradually
declined. Forty percent of the administered dose was excreted in the urine and 17% in
the feces. (Everett et al., 1966). Slightly less than 1% of the total dose was excreted in
the milk of cows fed 14C-methylene labelled AZM in the diet in the 3 days post-
treatment. Approximately 49% of the total radioactive milk residues were identified as
sugars (glucose and galactose) indicating that the methylene carbon was completely
metabolized and incorporated into sugars (Everett et al., 1966). Following a single
application of 14C labelled AZM (labelled carbon not specified) to the forearm of six
human subjects, 15.9% (SD = 7.9) of the applied radioactivity was excreted in the
urine after 120 hours post-exposure; 69.5% (SD= 6.9) was excreted in the urine
following IV administration (Feldman and Maibach, 1974).
AZM Metabolism
AZM metabolism occurs principally by oxidation of the P=S bond to the bioactive
oxon form, P =O, catalyzed by liver microsomal enzymes, with hydrolysis of the ester
bond so the leaving group forms a thiol (mercaptomethylbenzazimide) (Gallo and
Lawryk, 1991). Both cytochrome P450 and flavin-containing monooxygenase may be7
involved, although specific isoforms have not yet been identified (Sultatos, 1994;
Mileson et al., 1998). However, parathion, which is similar to AZM in chemical
structure, is believed to be oxidized to the oxon form by P450 2B1 (Sultatos, 1994).
The role of glutathione-s-transferase in AZM detoxification continues to be defined
(Sultatos and Woods, 1988; Sultatos, 1992). See Figure 1.2 for the metabolic scheme
of AZM in rats (from Watson, 1992). AZM itself has limited capacity for inhibiting
AChE. The AChE inhibiting compound is AZM oxon. The oxon is mainly formed in
the liver, the main site of P450 metabolism. Once AZM oxon is formed in the liver, it
enters systemic circulation traveling to the rest of the body.
OP Mechanism of Action
OP insecticides are designed to inhibit acetylcholinesterase. Two major forms of
cholinesterase have been characterized: acetylcholinesterase (AChE, E.C. 3.1.1.7) and
butyrylcholinesterase (BChE, serum cholinesterase, or pseudocholinesterase, E.C.
3.3.3.8). Generally, neural tissue contains AChE and non-neural tissue contains BChE;
however, in human blood, erythrocytes contain only AChE (located on the outside of
the cell membrane; Steck, 1974) while plasma contains BChE. Liver and lung contain
both esterases (Cooper et al., 1991). Because little work has been done on BChE and
no physiological role for that enzyme has been defined, use of the term cholinesterase
assumes AChE unless specified otherwise. (This is not to be confused with the term B-
esterase, to which group both cholinesterases belong. B-esterases are a class of
esterase that reacts with OPs, but8
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Figure 1.2 Metabolic scheme of azinphos-methyl in rats. (modified from Watson,
1992)9
becomes firmly, often irreversibly inhibited in the process. A-esterases hydrolyze OPs
to products that are no longer cholinesterase inhibitors.)
The neurotransmitter acetylcholine is present in all postganglionic parasympathetic
nerve endings, at myoneural junctions, and at both parasympathetic and sympathetic
ganglia. Under normal circumstances, cholinesterase rapidly hydrolyzes acetylcholine
into the inactive acetic acid and choline. OP insecticides bind covalently to the
acetylcholinesterase at the active serine hydroxyl site, phosphorylating the site and
thus inhibiting the enzyme. Water can regenerate the enzyme by dephosphorylation
but this is extremely slow, requiring hours to many days to occur. Spontaneous
regeneration is impossible if the process of aging occurs. Aging is nonenzymatic
dealkylation of the phosphate side-chain. The rate at which aging occurs varies with
OP structure (Sultatos, 1994). For clinical purposes, the OP-cholinesterase bond is not
spontaneously reversible without pharmacological intervention. See Figure 1.3 which
shows the interactions of acetylcholinesterase with (A) acetylcholine and (B) AZM
(Modified from Ware, 1994).
The inhibition of cholinesterase activity leads to the accumulation of acetylcholine
at synapses, causing overstimulation and subsequent disruption of transmission in both
central and peripheral nervous systems. Exposure to OP insecticides will, therefore,
interfere with synaptic transmission peripherally at muscarinic neuroeffector junctions,
at nicotinic receptors within sympathetic ganglia, at skeletal myoneural junctions, and
in at acetylcholine receptor sites within the central nervous system.(A) Acetylcholine
(B) Azinphos-methyl
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Figure 1.2 Simplified reactions of acetylcholine and azinphos-methyl with
acetylcholinesterase. (A) Acetylcholine is hydrolyzed to acetic acid and choline,
resulting in reactivated enzyme. (B) Azinphos-methyl is hydrolyzed and
phosphorylates the enzyme by attaching to serine at the esteratic site. Mercaptomethyl
benzazimide is released. (modified from Ware, 1994)
Inhibition of brain, erythrocyte, and plasma ChE are commonly used as
biomarkers of exposure to OPs. Inhibition of brain ChE (a biomarker of effect and
exposure) is typically only used in research settings (ie, in controlled laboratory
animal studies), but is occasionally used in cases of fatal human OP poisonings in
which brain tissue can be sampled. For human subjects, erythrocyte and/or plasma
ChE activity are often measured to determine if OP exposure has occurred. The
function of erythrocyte AChE and plasma BChE have not been determined.
Erythrocyte AChE and plasma BChE are not involved in nerve transmission and11
therefore inhibition of these enzymes is a biomarker of exposure, rather than of effect.
Animal studies show that inhibition of erythrocyte and plasma ChE are generally
correlated with inhibition of ChE in nerve tissue (Padilla et al., 1994), however, it has
been found that significant erthyrocyte and plasma ChE inhibition is sometimes
asymptomatic. This has been attributed to tolerance from repeated OP exposure that
results in decreased expression of acetylcholine receptors in nerve synapses (Hoskins
and Ho, 1992). Erythrocyte ChE is generally better correlated with brain ChE than
plasma ChE (Padilla et al., 1994), but this varies depending on the OP involved
(Gallos and Lawryk, 1991).
Acute Symptoms
Symptoms of organophosphate pesticide poisoning are generally due to their
ability to inhibit AChE. This inhibition leads to accumulation of acetylcholine at the
cholinergic synapses of the central nervous system (CNS), the neuromuscular
junction, parasympathetic nerve endings and some sympathetic nerve endings.
In a study of 70 adults (ages 15-60 years) treated for organophosphate or
carbamate poisoning in Jordan, the most common symptoms were: miosis (86%),
nausea and vomiting (73%), excessive salivation (73%), headache and dizziness
(63%), fever (49%), and abdominal pain or cramps (47%) (Saadeh, 1996). Symptoms
reported most frequently in a study of 37 children (ages 1 month-11 years) in Dallas,
Texas treated for organophosphate or carbamate poisoning included: miosis (73%),12
excessive salivation (70%), muscle weakness (68%), respiratory distress (59%),
lethargy (54%), and tachycardia (49%) (Zwiener, 1988). In a study of 236 cases of
organophosphate or carbamate poisoning in Israel (ages 1 month-71 years), the
symptoms reported most frequently were: vomiting (60.2%), abdominal pain (48.7%),
and miosis (44.1%) (Hirshberg, 1984).
Most of the symptoms of organophosphate poisoning are reversible. Some of the
cholinesterase enzyme will spontaneously recover. The portion of the enzyme that is
irreversibly phosphorylated will eventually be replaced by newly synthesized enzyme.
Acetylcholinesterase in the nerve cells is synthesized in each nerve cell and
transported to the synapse. Red blood cell acetylcholinesterase is replaced as the red
blood cells are replaced, at a rate of 1% per day, therefore red blood cell
acetylcholinesterase activity will return to normal in about 3 to 4 months. Plasma
cholinesterase is synthesized in the liver with levels generally returning to normal in a
few weeks.
Chronic Symptoms
While long-lasting neurological damage from acute-high level exposure to some
OPs is well documented, the possible consequences of chronic low-level exposures to
OPs, including AZM, are not well characterized (Mileson, 1998; Annau, 1992;
Chambers, 1992b). Several researchers have found behavioral changes (taste aversion,
stimulated flying, and postural changes) in animals treated with OP insecticides at13
doses that produced little or no cholinesterase inhibition (Hart, 1993; Roney et al.,
1986; Dutta et al., 1993).
Central nervous system toxicity, including memory impairment, depression,
schizophrenia, and confusion have been reported, but these effects are usually
transient (Tafuri, 1987). Other complications of OP poisoning include liver
dysfunction, heart dysfunction, psychosis, and delayed convulsions. There is strong
evidence that these complications are due to respiratory failure and subsequent
hypoxia and are not directly related to cholinesterase inhibition (Gallo and Lawryk,
1991).
Peripheral neuropathy, or organophosphate-induced delayed neuropathy (OPDIN)
has been reported occasionally and is characterized by persistent anesthesia,
parasthesia, and weakness of the extremities lasting months to years after exposure
(Tafuri, 1987). The cause of peripheral neuropathy is not clear, but it appears to follow
phosphorylation and subsequent aging of a protein in neurons called neuropathy target
esterase (NTE) (Marrs, 1993). Inhibition of NTE does not appear to be related to the
anticholinesterase effects of organophosphates (Marrs, 1993). Some organophosphates
with very weak anticholinesterase activity have been found to produce neuropathy
(Namba, 1971). A well-known example is triorthocresyl phosphate, an
organophosphate compound with very weak anticholinesterase activity and therefore
not used as an insecticide, but as a machine lubricant. Rum contaminated with
triorthocresyl phosphate caused 16,000 cases of peripheral neuropathy in the U.S. in14
1930-1931. This condition is also sometimes referred to as "Ginger Jake". Vegetable
oil contaminated with triorthocresyl phosphate in Morocco produced neuropathy in
11,000 people in 1959. Peripheral neuropathy due to commercial organophosphate
pesticides is rare considering the large number of incidents of acute poisoning world-
wide (Namba, 1971). Based on a review of AZM neurotoxicity studies, the EPA
determined that AZM does not cause OPIDN (EPA, 1998).
Diagnosis
Diagnosis of organophosphate poisoning is usually based on: 1) history or
evidence of exposure to an organophosphate, 2) characteristic signs and symptoms of
OP poisoning, 3) improvement of the signs and symptoms of OP poisoning after
administration of atropine, 4) inhibition of cholinesterase activity of the blood
(Namba, 1971). While these criteria may seem straightforward, initial diagnosis of OP
poisoning is not. In some cases, history or evidence of exposure is not present. The
most common symptoms of OP poisoning, abdominal pain and vomiting are easily
attributable to other causes (e.g. flu or heat stroke). Red blood cell and/or plasma
cholinesterase assays are not available at all hospitals and where available, take some
time to complete (Saadeh, 1996). In a study of 20 children transferred from emergency
rooms to a children's hospital, only four were correctly diagnosed with OP poisoning
at the time of transfer. Initial diagnosis in the emergency rooms ranged from
pneumonia, diabetic ketoacidosis, to shigellosis (Zwiener, 1988).15
Further complicating diagnosis are the limitations of the cholinesterase assay.
Inhibition of acetylcholinesterase results in accumulation of acetylcholine at
cholinergic synapses throughout the body. Because it is not feasible to measure the
acetylcholinesterase activity at the synapse, the diagnosis of OP toxicity is confirmed
by measuring the cholinesterase activity in the plasma or red blood cells. There are
several methods for measuring the activity of cholinesterase in plasma or red blood
cells. The units used for the different methods cannot always be interconverted,
making it difficult to compare results from one test to another. Results from different
labs cannot be readily compared because minor variations in the methods (pH,
temperature, substrate concentration) can significantly influence the results (Wilson,
1996a). There is wide variation in cholinesterase activity between individuals (Brock
and Brock, 1993; Johnson, 1993), thus the normal range is very broad. An individual
with high normal activity, could have significant inhibition of cholinesterase, but still
fall within the normal range.
OP exposure can also be monitored by the presence of dialkylphosphate
metabolites in the urine (Drevenkar, et al., 1991 and McCurdy, et al., 1994).
Metabolism of AZM results in three dialkylphosphates in the urine:
dimethylphosphate, dimethylthiophosphate, and dimethyldithiophosphate. Many other
OPs produce the same urinary metabolites, therefore this method is not specific to
AZM. While this method can detect low-level exposure, the rapid elimination of
urinary dialkylphosphate metabolites makes them useful for assessing only recent
exposures (less than 48 hours) (McCurdy, et al., 1994).16
Treatment
Decontamination, atropine, enzyme reactivators, and symptomatic care constitute
the most important means of treating poisoning by organophosphates in humans
(Gallo and Lawryk, 1991; Zweiner, 1988).
Initial treatment should include removal of contaminated clothing and thorough
cleansing of the skin. Organophosphates can be absorbed through the skin and the skin
can act as depot leading to continued exposure. If the OP was ingested, gastric lavage
should be performed to remove the compound from the stomach.
Atropine is a muscarinic cholinergic blocking agent, first isolated from the deadly
night shade plant (atropa belladonna) in 1831 (Marrs, 1993). Atropine was once used
by women as a beauty aid. Drops of atropine were placed in the eyes, dilating the
pupils and making the eyes appear larger. Atropine binds to the muscarinic receptors
in the nerve synapse, thus preventing acetycholine from binding. Atropine, therefore,
relieves only the muscarinic symptoms.
Enzyme reactivators are used to remove the phosphate group from inhibited
AChE, thus unblocking the active site and restoring the function of the enzyme. The
oximes in clinical use are salts of pyridine 2-aldoxime (2-PAM). They are only
effective prior to aging of the enzyme, therefore oxime treatment must be given
shortly after exposure to be effective. The time it takes for aging to occur varies with17
the OP involved. Generally aging occurs within a few hours after exposure, but with
some OPs (eg chlorpyrifos and parathion) aging can take days (Wilson et al., 1992).
The time for AZM to age has not been reported, but it probably is similar to other
dimeoxy OPs (eg dimethoate and malathion), which have aging half-lives of 2.0-8.9
hours (Wilson, et al., 1992).
Biomonitoring of Occupational AZM Exposure
A number of studies have been conducted on agricultural workers who were
occupationally exposed to AZM (Kraus et al., 1977; Franklin et al., 1986; Schneider et
al., 1990; Drevenkar, et al., 1991; Schneider et al., 1994; Spencer et al., 1995;
McCurdy et al., 1994). Biomonitoring methods in these studies included collecting
blood and/or urine samples for ChE and urinary metabolite measurements. While
these studies were able to correlate ChE inhibition and/or detection of urinary
metabolites with AZM exposure, a number of problems with these studies were noted,
including: 1) wide individual variation in ChE activity (Kraus et al., 1977) 2) low
recovery of dialkylphosphates in urine (25 to 64%) (Kraus et al., 1977), 3) difficulty
getting complete 24 hour urine samples from workers (Schneider et al., 1990;
Drevenkar et al., 1991), 4) urinary metabolites do not indicate cumulative exposure
(McCurdy et al., 1994), 5) urine samples must be collected within 2 days to be of use
(McCurdy et al., 1994), 6) need for assessment of aggregate exposure occurring over
several months that is based on sensitive, specific biomarkers documenting individual18
exposure (McCurdy et al., 1994), and 7) difficulty in comparing ChE results
conducted at different laboratories (Schneider et al., 1994).
Hemoglobin Adducts as Biomarkers of Xenobiotic Exposure
The use of biomarkers for estimating risk from xenobiotic exposure is of growing
interest. Current risk assessment methods often rely on measurements of chemicals in
environmental media (soil, water, air, and food) to estimate exposure (Fowle and
Sexton, 1992). However, in many cases environmental media concentrations do not
give an accurate measure of the internal dose (National Research Council, 1987).
Exposure estimates are often the weakest link in the risk assessment process (Schnell,
1993). Biomarkers provide better, more accurate characterizations of actual human
health risks and provide a more solid scientific basis for risk assessment (Fowle and
Sexton, 1992).
The National Research Council Committee on Biological Markers defines
biomarkers as: "indicators signaling events in biological systems or samples"(1987).
Biomarkers are classified into 3 categories: effect, exposure, and susceptibility.
Biomarkers of effect are indicators of an endogenous component of the biological
system, a measure of the functional capacity of the system, or an altered state of the
system that is recognized as impairment or disease. Examples of biomarkers of effect
are brain AChE inhibition, DNA adducts, and P450 inhibition. Biomarkers of
susceptibility indicate that the health of the system is especially sensitive to the19
challenge of exposure to a xenobiotic. Examples of biomarkers of susceptibility are
genetic markers that indicate an individual may not produce enzymes necessary for
detoxification of certain xenobiotics. A biomarker of exposure is an exogenous
substance within the system, the interactive product between a xenobiotic compound
and an endogenous compound, or other events in the biological system related to
exposure. Examples of biomarkers of exposure are hemoglobin and albumin adducts
produced by exposure to xenobiotics, parent xenobiotic in the blood or urine, and
inhibition of erythrocyte AChE and plasma BChE. My research has focused on
hemoglobin adducts as biomarkers of exposure.
Research into protein adducts as biomarkers of exposure grew out of research on
biomarkers of carcinogenic compounds. One of the main biomarkers of exposure and
effect of carcinogen exposure is the formation of DNA adducts. Carcinogens act by
altering the function of genetic material, and many carcinogens bind to DNA. There is
a large body of research on DNA adducts as biomarkers of exposure. Limitations for
using DNA adducts for biomarkers of exposure include limited quantities of DNA
available in a typical blood sample and low levels of DNA adducts due to efficient
DNA adduct repair mechanisms (Timbrell, 1998; Schnell, 1994). Many carcinogens
also bind to blood proteins (Van Welie et al., 1992). Researchers found hemoglobin
possessed many of the qualities necessary for a good biomarker including: large
quantities available in a typical blood sample, adduct stability (ie no repair of
hemoglobin adducts; Vainio, 1995), the ability to measure retrospective exposure for
up to several months due to the relatively long lifespan of hemoglobin in humans20
(-120 days), and dose-dependant binding (Van We lie et al., 1992; Schnell, 1994;
Henderson et al., 1989). Serum albumin adduction has also been studied as a
biomarker of exposure. It has the advantage of being easily available for adduction (no
cell membrane) and also is available in large quantities in the blood, but has the
disadvantage of a much shorter lifespan than hemoglobin ( --20 days in humans)
(Farmer et al., 1987). For some applications, albumin adducts have been found more
useful than hemoglobin adducts, but for most applications hemoglobin adducts have
been found in higher amounts than albumin adducts and therefore is most often used
as a biomarker of exposure. It is important to keep in mind that no single biomarker
will be adequate for all applications. "An ideal biomarker of exposure is one that is
chemical specific, detectable in trace quantities, available by noninvasive techniques,
inexpensive to assay, and quantitatively relatable to a prior exposure... Few if any
biomarkers will have all these characteristics, but many nonideal biomarkers can be
useful for specific purposes" (Henderson et al., 1989).
Hemoglobin Adduct Formation and Elimination
Electrophilic chemicals or their metabolites bind to nucleophilic sites on
hemoglobin. The most common adduction sites on hemoglobin include (in decreasing
order): the sulfhydryl group of cysteine, the N-terminal amino nitrogen of valine, and
the ring nitrogens of histidine (Schnell, 1993). Adducts also occur at the nitrogen of
lysine, the ring nitrogen of tryptophan, the sulfur of methionine, the hydroxyls of
tyrosine, threonine and serine; and the carboxyls of aspartic and glutamic acid21
(Schnell, 1993; Tornqvist, 1995). The cysteine on the beta chain of hemoglobin at
position 93 has been shown to be particularly reactive, perhaps due to its proximity to
the heme (Schnell, 1993).
Kinetics of formation and elimination of hemoglobin adducts have been described
by Fennel et al. (1992). Hemoglobin adducts tend to form in a dose-dependent
manner. As with most biochemical reactions, it can be saturated at high doses, but at
environmentally relevant doses, this would rarely occur. With a single exposure,
hemoglobin adducts usually reach their highest levels within minutes or hours of
exposure, depending on whether they are direct-acting or require metabolism. The
hemoglobin adducts decline with time as the erythrocytes are replaced, which in
humans takes 120 days. Some researchers have reported a linear decline of adducts
(Osterman-Golkar et al., 1976, Segerback et al., 1978), others report a non-linear
decline (Sabbioni and Neumann 1990, Walker et al., 1993, Viau et al., 1993, Neumann
et al., 1993, Wilson P.M.et al., 1996). Fennel et al. (1992) reports that following a
single exposure if the adduct is stable and the erythrocytes are replaced as they age,
the decline will be linear. However, some erythrocytes are replaced randomly (ie
regardless of how old they are) and some adducts are unstable. These conditions result
in nonlinear elimination. Repeated or chronic exposure will lead to an increase of
hemoglobin adducts with time until a steady state is reached (when the rate of
elimination equals the rate of formation, which is the erythrocyte lifespan) and then
decline non-linearly after the last exposure.22
Hemoglobin Adducts of Pesticides
Hemoglobin adducts of pesticides were reviewed by Schnell (1993). He reported
that 38 pesticides form hemoglobin adducts or unspecified erythrocyte proteins.
Unfortunately, 17 of the 38 pesticides reported to form adducts are cited by a single
source (Lewalter and Korallus, 1986), which does not include any information on the
methods used to identify the adducts and therefore is of limited value. Of the 21
chemicals cited by other sources, 10 are arylamine derivatives, 1 is an
organophosphate (dichlorvos), 2 are carbamates, 3 are triazines, 1 is phenolic
(pentachlorophenol), and 4 are unclassified (ethylene dibromide, monochloroacetic
acid, naphthalene, and trichloroacetonitrile). The arylamine derivatives have been well
characterized and are easily detected by acid hydrolysis and GC/MS. Many of the
other pesticide adducts were not well characterized at the time of Schnell's review.
Since 1993 more research on pentachorophenol hemoglobin adducts has been reported
(Waidyanantha et al., 1996) and two additional pesticides have been added to the list
of hemoglobin adduct forming pesticides: the miticide dienochlor (Fruetel et al., 1994)
and the fumigant methyl bromide (Goergens et al., 1994).
OPs and carbamate pesticides are unique in that there exists a biomarker of their
exposure due to the fact that OPs and carbamates inhibit ChE. Few biomarkers exist
for most other types of pesticides. Many of the pesticides in use today do not
bioaccumulate and are rapidly eliminated, therefore, looking for the parent compound
in the blood or urine is of limited use as biomarkers of exposure.There is a need for23
developing other chemical specific biomarkers for pesticides. Hemoglobin adducts
have many qualities that make them a potentially good biomarker for meeting this
need.
Analytical Methods for Protein Adducts
Since Osterman-Golkar et al. first suggested using hemoglobin adducts as
biomarkers of exposure in 1976 there have been a number of advances in methods for
quantitative and qualitative analysis of hemoglobin adducts. Early researchers in this
field were limited to the use of radiolabled compounds to detect and quantify
hemoglobin adducts, however, this method provides no structural information about
the adducting compound (Osterman-Golkar et al., 1976, Pereira and Chang, 1981;
Pereira et al., 1981; Segerback and Ehrenberg, 1981). Two other methods were
introduced in the early 1980's. One was mild acid or base hydrolysis to release the
adducted compound from the protein, followed by isolation of the free adduct
molecule by extraction or column chromatography. The cleaved adduct is derivatized
and analyzed most commonly by GC/MS but sometimes by HPLC with fluorescence
detector. The second was complete acid hydrolysis of the protein breaking it into
individual amino acids. Adducted amino acids are then analyzed by ion exchange
chromatography, HPLC, or GC. In 1986, Tornqvist et al. introduced a new technique
using a modified Edman degradation to identify and quantitate hemoglobin adducts.
This technique involves removing terminal valines from hemoglobin followed by
derivitization and GC or GC/MS (Tornqvist et al., 1986). These four techniques have24
been, and still are, the main tools for hemoglobin adduct analysis. In 1988, Meng et al.
introduced a new ionization method for mass spectrometry of proteins that paved the
way for a new tool for hemoglobin adduct analysis: electrospray or ionspray ionization
mass spectrometry (ESI/MS). ESI/MS allows for analysis of intact adducted
hemoglobin or adducted peptides. Commercial ESI/MS instruments became available
in the early 1990's. Immunological techniques are believed to show great promise in
the analysis of hemoglobin adducts, but few papers have been published using
immunological methods of detection.
Of course, each of these methods has advantages and disadvantages. Some
methods are useful for analysis of certain kinds of adducts, but not for others. Table
1.1 summarizes the methods, applications, detection limits, advantages, and
disadvantages. We chose ESI/MS for analysis of intact adducted hemoglobin in our
experiments. This method has been used successfully by several researchers (Farmer
et al., 1995; Frantzen et al., 1997; Birt et al., 1998; and Li et al., 1999).
ESI/MS of Proteins
ESI/MS is a mass spectrometric technique that generates accurate molecular mass
information on intact proteins or peptides. ESI/MS samples are introduced into the
mass spectrometer as a liquid. Sample ions are formed as a result of spraying the
liquid (water/organic mobile phase) containing the protein or peptide into a region of
high electric potential at atmospheric pressure. As the liquid passes through the25
electric potential it forms small droplets with electric charges on their surface. The
resulting multiply charged, gas-phase ions can be mass analyzed by a variety of mass
spectrometers. We used a quadrupole and an ion trap mass spectrometer, both
equipped with for electrospray ionization, in our research.
A unique feature of ESI is the formation of a number of signals in the mass
spectrum which result from the multiple charge states of the molecule. All of these
multiply-charged ions can be used to calculate the mass of the sample protein or
peptide using the observed mass and the charge state of each ion (Scoble et al., 1993).
On average, one charge is added per 1000 Da in mass. Because mass spectrometers
separate ions by their mass-to-charge ratio (m/z), rather than their mass, an ion of
mass 10,000 which carries 10 charges will be recorded at m/z 1000 (Chapman, 1996).
An ESI mass spectrum of a protein is characterized by a series of peaks caused by ions
carrying different numbers of charges (and thus exhibiting different mass-to-charge
values) (Borman, 1995). A sample ESI spectrum is shown is Figure 1.4. Note the
distinct pattern of peaks (described as a "protein envelope") with a somewhat gaussian
shape and the peaks getting slightly farther apart as the m/z increases.
ESI/MS is a very mild procedure which does not fragment the analyte, therefore
intact proteins or peptides can be analyzed. Individual amino acids up to proteins >100
kDa can be analyzed by ESI/MS. Without fragmentation, only molecular weight
information can be gathered. If structural information is desired, tandem MS (MS/MS)26
Table 1.1 Summary of Hemoglobin Adduct Analytical Methods
Method DetectionDetection Limit
(mol/g
hemoglobin)
ApplicationsAdvantagesDisadvantages
radiolabelled
compounds
LSC, HPLC
with radiomatic
detector,
combustion
pmol/g-nmol/gany
radiolabelled
compound
high
sensitivity,
useful even
when
structure of
adduct is
unknown
provides no
structural
information
about
adducted
molecule
mild acid or
base
hydrolysis
derivitization,
GC/MS or
HPLC with
fluorometric
detector
10-20 pmol/garomatic
amines and
PAHs
simple only
applicable to
acid or base
labile
compounds
complete
protein
hydrolysis by
acid or
enzymes
HPLC cleanup,
ion exchange
chromatograph
or GC/MS
pmol/g-nmol/gwidely
applicable
widely
applicable
tedious; harsh
conditions
may lead to
artifacts
and/or loss of
adduct
modified
Edman
degradation
GC/MS 1-10 pmol/galiphatic
epoxides
simple only
applicable to
adducts bound
to terminal
valines, can
be insensitive
because of
low levels of
adduction
immunologic
al
ELISA 0.1 pmol/gwidely
applicable
high
sensitivity
must have
available
antibody
ESI/MS of
peptides or
intact
hemoglobin
ESI/MS lpmol of
adducted
protein
widely
applicable
widely
applicable
may not
applicable for
routine
monitoring27
can be used, which does fragment the analyte, and information can be gathered from
the fragments produced (Chapman, 1996).
Experimental Approach to the Problem
The initial aims of our research were to look for a dose-dependent and stable AZM
hemoglobin adduct. We began our research using radiolabelled AZM for several
reasons:1) No previous research on AZM hemoglobin adducts had been conducted, so
the first step was to determine whether or not AZM formed a stable, dose-dependent
association with hemoglobin. This goal could be most easily achieved using
radiolabelled material. 2) Bayer Corporation was kind enough to provide us with some
radiolabelled AZM at no cost. This was a significant help to our research since
radiolabelled AZM is not commercially available and even had it been available the
cost would probably have prevented us from conducting our experiments.
Based on initial findings we did further experiments to understand the nature of the
AZM hemoglobin adduct and its binding site. We decided to use ESI/MS, a relatively
new technique at the time, for hemoglobin adduct analysis. We chose this technique
over some of the more established methods for hemoglobin adduct analysis for several
reasons: 1) ESI/MS is less likely to produce artifacts than some of the other techniques
(eg acid hydrolysis). 2) ESI/MS can provide more information about the adducted
compound because it will provide the molecular weight of the adduct, and if we used
ESI/MS/MS (tandem MS) we could also get structural information about the100
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Figure 1.4 ESI/MS of the alpha2 globin of rat hemoglobin. MW = 15,194.67 +/- 1.64
adduct, as well as possibly identifying the site(s) of adduction on the protein. 3) The
Mass Spectrometry facility at OSU had an ESI/MS available. At the time we began
our research, this was a unique resource not available to most hemoglobin adduct
researchers.29
We knew we would be pushing the limit of detection and it turned out to be the
case. To address this outcome, we conducted in vitro experiments using a liver
microsome system for incubating AZM with hemoglobin to increase the molecular
ratio of AZM to hemoglobin and therefore increase the concentration of adducted
hemoglobin.30
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Introduction
U.S. growers commonly use the organophosphate insecticide, azinphos-methyl
(AZM), on a variety of crops, which include cotton, apples, pears, sugar cane, and
cranberries. Each year, growers apply more than 1 million pounds to crops (Schreiber
1997). Agricultural laborers who work in treated fields are frequently exposed to AZM
(Drevenkar et al., 1991; McCurdy et al., 1994).
Organophosphate insecticides are designed to inhibit acetylcholinesterase (AChE,
E.C. 3.1.1.7), the enzyme that hydrolyses the neurotransmitter acetylcholine in nerve
and muscle tissue. In the presence of an organophosphate, synaptic acetylcholine
levels may rise to abnormally high levels, resulting in repetitive stimulation of
muscarinic and nicotinic receptors in target tissues. At sufficiently high exposure
levels, this produces clinical signs of acute cholinergic poisoning. Complete recovery
is usual if the individual is removed from further exposure, allowing clearance of the
organophosphate from the body and a return to normal levels of synaptic
acetylcholine. However, long-lasting neurological damage from acute high-level
exposure to some organophosphates is well documented (Karczmar, 1984). The
mechanism for long-lasting neurological damage is not clear. It may involve another
enzyme, neuropathy target esterase (NTE), rather than cholinesterase.
Possible consequences of long-term low-level exposure to organophosphates are
not well characterized (Annau, 1992; Chambers, 1992b; Mileson et al., 1998). Several32
studies have found significant behavioral changes in animals treated with
organophosphate insecticides at doses that produced little or no cholinesterase
inhibition (Hart, 1993; Kurtz, 1977; Roney et al., 1986; Dutta et al., 1993). AZM is
often applied two or three times over several months, and workers may enter treated
areas more than once after these applications. Therefore, agriculture workers often are
exposed repeatedly to AZM over a period of days, weeks, or months.
Available AZM exposure monitoring methods have limited use for detecting long-
lasting low-level exposure. Acute AZM exposure in humans is generally monitored by
measuring plasma, erythrocyte, or whole blood cholinesterase inhibition. Blood
cholinesterase activity does not appear to be involved in neurotransmission (the
function of cholinesterases present in the blood is not known), but inhibition of these
enzymes is used as a biomarker of exposure to organophosphates. Wide individual
variation in blood cholinesterase activity requires pre-exposure testing and limits its
use as a quantitative biomarker of internal dose, especially at low exposure levels
(Sanz et al., 1991; Brock and Brock, 1993).
Organophosphate exposure can also be monitored by the presence of
dialkylphosphate metabolites in urine (Drevenkar et al., 1991; McCurdy et al., 1994).
While this method can detect low-level exposure, the rapid elimination of urinary
dialkylphosphate metabolites makes them useful for assessing only recent exposures,
i.e., less than 48 hours (McCurdy et al., 1994).33
A hemoglobin adduct that is specific for AZM exposure would be more useful
than cholinesterase or urinary metabolites for monitoring chronic AZM exposure
(Schnell, 1994). Adducts with hemoglobin are useful biomarkers of long-term
exposure because hemoglobin's long biological lifetime (120 days in humans) results
in dose-dependent accumulation of adducts to steady-state levels (Skipper and
Tannenbaum, 1990). Hemoglobin adducts have been identified for a number of
pesticides or their metabolites including pentachlorophenol (Waidyanatha et al.,
1996), linuron (Sabbioni and Neumann, 1990), ethylenebisdithiocarbamates (Pastore lli
et al., 1995), and the organophosphate insecticide dichlorvos (Segerback and
Ehrenberg, 1981).
We hypothesize that an AZM metabolite (Fig. 1.1) forms an adduct with
hemoglobin. AZM is rapidly cleared from mammals, with 85-100% of the
administered dose eliminated in urine and feces within 48 hours (Watson, 1992).
However, pharmacokinetic studies conducted with [14C]AZM demonstrated that a
small amount (less than 1%) of radioactivity from a single dose administered to rats
was still evident in the erythrocytes for up to 16 days (Watson, 1992). When whole
blood was incubated with labeled parent compound, no accumulation of radioactivity
in the blood constituents was found (Watson, 1992). Therefore, it is likely that it was a
metabolite of AZM that persisted in the erythrocytes. We investigated whether there
was a dose-dependent association of radioactivity with erythrocytes and hemoglobin
collected from rats treated with [14C]AZM and whether the association was stable in34
vivo. These are requisite if hemoglobin is to serve as a biomarker of human AZM
exposure.
Materials and Methods
Materials
Bayer Corporation, Stillwell, Kansas, provided [14C]AZM (ring labeled, 92.99%
pure, specific activity 46.9 mCi/mmol, radiochemical purity >95%). Acetone, glass
distilled; corn oil, Mazola 100% pure; rats, Sprague-Dawley from Simmonson
Laboratories, Gilroy, California; diet, Harlan Takled Rodent Diet; NCS-II tissue
solubilizer, Amersham Life Science, Arlington Heights, Illinois; glacial acetic acid,
J.T.Baker; benzoyl peroxide, Sigma, St. Louis, Missouri, 70% pure (remainder water);
toluene, Burdick and Jackson Laboratories, Inc., Muskegon, Michigan, gas
chromatography grade; Complete Counting Cocktail 3a70B, Research Products
International Corp., Mount Prospect, Illinois; 5,5'-dithiobis-2-nitrobenzoic acid
(DTNB), Sigma; acetylthiocholine iodide (ATCh substrate), Sigma;
tetraisopropylpyrophosoramide (iso-OMPA), Sigma; phosphate buffer, Sigma; 96-
well plates, Corning, cat. no. 25880-96.
Animals and treatments
We housed 30 male Sprague-Dawley rats (216-244 g at time of treatment)
individually in stainless steel metabolism cages with free access to food and water.Rats were maintained under controlled conditions of temperature (22 +/- 2 °C) and
humidity (50 + 10%) and a light/dark cycle of 12 hours. Animals had an adjustment
period of at least 1 week prior to treatment. [14C]AZM was dissolved in acetone and
suspended in corn oil (2% acetone v/v;
35
1 mg [14C]AZM /m1 vehicle). Gavage solution
was prepared fresh the day before administration and stored at 4 °C until use. Gavage
solution was analyzed by radiometric HPLC to confirm the AZM concentration prior
to administration. Control animals received corn oil with 2% acetone (v/v). In
Experiment 1(dose-response), there were four treatments (0, 1.5, 3, and 6 mg/kg)
administered by gavage. Each animal received a single treatment. There were three
animals per treatment group. Control animals (0 mg/kg) received 2% v/v acetone in
corn oil. For comparison, the lethal dose to 50% of animals tested (LD50) of AZM in
adult female Sprague-Dawley rats is 16.4 mg/kg (Dubois et al., 1957). Three days
after administration of [14C]AZM, Experiment 1 animals were sacrificed. Brain and
blood tissue were collected when the animals were sacrificed. Animals were
anesthetized with CO2 before exsanguination. In Experiment 2 (time course), there
were two treatments, 0 and 3 mg/kg, administered by gavage, with 12 animals per
treatment. Each animal received a single treatment. Three animals from each treatment
group were sacrificed 3, 11, 15, and 22 days after[14C]AZM administration. Brain and
blood were collected when the animals were sacrificed. Blood (about 1.5-3 ml per
animal) was collected by cardiac puncture or from the abdominal vena cava into
heparinized vacutainers and stored at 4 °C until processing. Whole brains were
removed, placed in 3 mL cryotubes, frozen in liquid nitrogen, and stored at -80 °C
until analysis. All animal-use procedures were in strict accordance with the National36
Institutes of Health Guide for the Care and Use of Laboratory Animals and were
approved by the Animal Care Committee of Oregon State University.
Quantification of Radioactivity in Erythrocytes
Blood was centrifuged (2,000 rpm, 5 min, at 10 °C) to separate erythrocytes from
the plasma. Plasma samples were placed in microcentrifuge tubes and stored at -80 °C
until analysis. Erythrocytes were resuspended in one volume of isotonic saline
solution (0.9% sodium chloride) and stored overnight at 4 °C. The following day, the
erythrocytes were washed three times with isotonic saline solution and resuspended in
one volume of saline solution. An aliquot (2004 ) of each erythrocyte sample was
placed in a 20 mL liquid scintillation vial. Samples were prepared for liquid
scintillation counting using the protocol for NCS-II tissue solubilizer (Amersham Life
Sciences Product Data Sheet, 1992). NCS-II tissue solubilizer (1mL) was added to
each vial, mixed, and vials placed in a 50 °C water bath for 30 min. Vials were
removed from the water bath and placed in a 37 °C incubator overnight. The following
day, a decolorizing solution of benzoyl peroxide was prepared. Benzoyl peroxide (1 g)
was placed in a flask and 5 mL toluene added. The solution was heated to 60 °C for 10
min, cooled to room temperature, and filtered. Benzoyl peroxide solution (400 p,L)
was added to each vial of erythrocytes, the vials were mixed, and then placed in a 50
°C water bath for 30 min. After removing vials from the water bath and allowing them
to cool to room temperature, the pH of each vial was checked using pH paper.
Counting efficiency is maximized when the pH is between 6-7. If the pH was too high,37
10 µL aliquots of glacial acetic acid were added until the pH was 6-7. No more than
20 !IL of glacial acetic acid was required to adjust the pH. Complete Counting
Cocktail (18 mL) was added to each vial. Vials were inverted several times to mix and
placed in the dark to exclude light and reduce chemiluminescence prior to counting the
samples. Samples were placed in a Packard Tri-Carb Liquid Scintillation Analyzer
(model 1900CA) the following day. Samples chemiluminesced for about 4 days. Data
was collected after control sample readings stabilized.
Quantification of Radioactivity in Hemoglobin Samples
After 200111_, aliquots of erythrocytes were removed for liquid scintillation
analysis, hemoglobin was isolated from the rest of the erythrocyte samples using the
Antonini and Brunori method (1971). After centrifuging and discarding the
supernatant of the erythrocyte samples, the erythrocytes were lysed by the addition of
three volumes of cold distilled water and allowed to stand for 30 min at 4 °C.
Membrane proteins were precipitated by adding saturated ammonium sulfate and
allowing the mixture to stand for 45 min. The lysate was centrifuged at 10,000g for 30
min on a Sorvall centrifuge (4 °C), after which the clear supernatant (hemoglobin
solution) was transferred to dialysis tubing. The hemoglobin solution was dialyzed
against three changes of 0.05 M phosphate buffer (pH 7.0) for 36 h. Dialysis caused
unexpected precipitation of the hemoglobin. In order to accurately measure the
hemoglobin concentration, the samples were gently mixed to resuspend the
hemoglobin prior to removing aliquots for concentration measurement and liquid38
scintillation spectrometry. The hemoglobin isolated from blood collected 22 days after
dosing was not dialyzed to prevent precipitation of hemoglobin. The hemoglobin
solution was stored at 4 °C and used within 2 weeks. Hemoglobin concentration of the
solutions was measured using Sigma Diagnostics Total Hemoglobin Kit, cat. no. 525-
A. Aliquots (200 iiL) of the hemoglobin solutions were placed in 20 mL liquid
scintillation vials and processed in the same manner as the erythrocytes.
Cholinesterase Activity Measured in Brain Tissue and Plasma
Whole brains were thawed on ice and homogenized on ice in a 1% Triton X-200
sodium phosphate buffer (pH 8) with a final dilution of 1:25 (volume:volume).
Aliquots (30 4) were removed and analyzed for AChE activity by the Ellman method
modified for microtiter plates (Wilson, et al., 1996a). Plasma was thawed at room
temperature and 30 4 analyzed for AChE activity by the Ellman method as modified
for microtiter plates (Wilson, et al., 1996a). Tissues collected at each time point were
assayed on the same day. The assay was adapted for use with a microtiter plate reader
(SpectraMAX 250 by Molecular Devices with SOFTmax Pro software). The tissue
samples were placed in microtiter plates in triplicate. DTNB (final concentration=
0.32 mM) and 50 4 0.1 M sodium phosphate buffer (pH 8) were added. The plates
were preincubated at room temperature for 5 min. After preincubation, the ATCh
substrate was added (final concentration = 1.0 mM), and the volume was brought up to
320 pL with 0.1 M sodium phosphate buffer (pH 8). Each plate was run with substrate
and tissue blanks. The samples were read kinetically for 5 min, during which time 2839
separate absorbance readings were taken for calculating the mean change in mOD
(millioptical density)/min. The assay was run at room temperature (-25 °C). Rat
plasma contains 50:50 AChE (E.C. 3.1.1.7): butyrlylcholinesterase (BChE)
(E.C.3.1.1.8) (Traina and Serpeitri, 1984). Iso-OMPA (final concentration = 100 [tM)
was added to the plasma samples to inhibit BChE so that only AChE activity was
measured.
Hemoglobin Adduct Removal Model
We used the hemoglobin adduct removal model of Fennel et al. (1992). We used
the following equation:
Y = [a(t-t2 /2ter)at(f)/tedek(t
which describes hemoglobin adduct removal following a single exposure where:
y = adduct concentration (disintegrations per minute (dpm)/mg hemoglobin)
t = time of exposure (for a single exposure, t =1)
t' = time since onset of exposure (varies from 0 to ter)
ter = lifespan of erythrocyte [61 days for Sprague-Dawley rats (Dere lanko, 1987)]
a = daily increment of adduct formation (512 dpm/mg hemoglobin)
k = random loss of erythrocyte/day and/or adduct instability (0.014, calculated using
least squares regression analysis of our time-course data)
The daily increment of adduct formation for a single exposure is the adduct
concentration on day 1(the day of treatment). Our first data point was collected on day
3; therefore, we calculated the concentration on day 1 using least squares regression
analysis of our time-course data.40
Statistical Analysis
We used Graph Pad Prism version 1.00 computer program for linear and non-linear
regressions. We used Splus version 4.5 for least-squares regression.
Results
We found a dose-dependent association of radioactivity with erythrocytes (Fig.
2.1) and hemoglobin (Fig. 2.2) in blood collected from animals 3 days after treatment
with a single dose of 1.5 mg/kg, 3 mg/kg, or 6 mg/kg [14C]AZM. A comparison of the
radioactivity levels in Fig. 2.1 and Fig. 2.2 (with adjustments for erythrocyte
hemoglobin concentration) suggests that most (if not all) of the radioactivity in the
erythrocytes is associated with hemoglobin. Whole rat blood contains 146 mg
hemoglobin/ml whole blood (Schalm, 1986). The average hematocrit measured in this
experiment was 0.52.Therefore, there is 280 mg hemoglobin/ml erythrocytes.
We found radioactivity continued to be associated with erythrocytes (Fig. 2.3) and
hemoglobin (Fig. 2.4) 11, 15, and 22 days after treatment with a single dose of 3
mg/kg [14C]AZM. Both a linear regression and an exponential decay curve fit the data
well with r2 values greater than 0.90 for erythrocytes and hemoglobin data. Rat
erythrocyte elimination appears to be best described by an exponential decay function
(Neumann et al., 1993). Therefore, we show our data in Fig. 2.3 and 2.4 fitted withan
exponential decay curve.300000_
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Figure 2.1 Dose response of [14C]AZM with erythrocytes 3 days post-exposure (mean
+/- SD, n = 3, r2 = 0.993)
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Figure 2.2 Dose response of [IMAZM with hemoglobin 3 days post-exposure (mean
+/- SD, n = 3, r2 = 0.997, before extraction with organic solvents)42
Our time-course data also fit the physiologically-based pharmico-kinetic
hemoglobin adduct removal model well (see Fig. 2.5). The AZM hemoglobin adduct
half-life calculated according to the method of Rumack and Lovejoy (1986) using the
time-course data (Fig. 2.4) is 20.6 days (95% confidence interval of 17.7 to 24.6 days;
r2 = 0.95).
Table 2.1 shows the AChE activity 3 days after animals received a single dose of
1.5 mg/kg, 3 mg/kg, or 6 mg/kg [14C]AZM. Table 2.2 shows the AChE activity 3, 11,
15, and 22 days after animals received a single dose of 3 mg/kg [14C]AZM. We
observed no overt signs of organophosphate intoxication--lacrimation, salivation,
diarrhea, tremors--in any of the treatment groups.
Table 2.1 Average AChE activity 3 days after treatment [%control (+/- SD) n = 3]1
Tissue [14C]AZM (mg/kg)
1.5 3.0 6.0
Brain 100.8 (2.1) 95.9 (5.4) 93.0 (4.3)
Plasma 91.9 (8.6) 102.1 (21.2) 102.9 (4.0)
All 3 treatment groups (1.5, 3.0, and 6.0 mg/kg AZM; n=3 for each group) were compared to the same
control group (n=3). The control group was sacrificed on the same day as the treatment groups.
Table 2.2. Average ChE Activity after treatment with 3.0 mg/kg [14C]AZM [% control
(+/- SD) n = 3]'
Tissue Days post-exposure
3 11 15 22
Brain 95.9 (5.4) 87.5 (1.8) 94.5 (1.9) 97.6 (3.3)
Plasma 102.1 (21.2) 99.7 (6.5) 81.0 (12.4) 81.1 (14.8)
There was a control group (n=3) for each time-point. The treatment group sacrificed at each time-point
was compared to the control group sacrificed at each time-point.43
Both human and rat nerve tissue contain AChE. Human plasma contains only
BChE, but rat plasma is a mixture of approximately 50% BChE and 50% AChE. Both
human and rat erythrocytes also contain AChE. In this study, we measured AChE in
whole brain tissue and AChE in the plasma. Erythrocyte AChE activity was not
measured.
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Figure 2.3 Stability of [14C]AZM associated with erythrocytes (mean +/- SD, n=3,
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Figure 2.4 Stability of [14C]AZM associated with hemoglobin (Mean +/- SD, n = 3, r2
= 0.96, before extraction with organic solvents)
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Figure 2.5 Comparison of observed adduct removal in rats receiving a single dose of 3
mg/kg [14C]AZM with the modeled results45
Discussion
The results of this study indicate that an AZM metabolite had a dose-dependent
affinity for erythrocytes and hemoglobin in vivo at doses that caused no observable
adverse acute effects and that did not result in marked brain or plasma AChE
depression. Symptoms of organophosphate intoxication generally occur when brain or
plasma (or both) cholinesterase activity is more than 20% inhibited (Sheets et al.,
1997). In this experiment, the highest observed level of AChE inhibition in brain or
plasma was 19%. Pasquet et al. (1976) found the greatest inhibition of rat plasma ChE
after a single administered orally dose of 6 mg/kg AZM 5 hr postexposure, and brain
AChE was most inhibited 2 hr post-exposure. We collected samples beginning 3 days
post-exposure when brain and plasma ChE activity would have returned to normal
levels, if they had been inhibited earlier.
There was an unexpected trend towards increasing plasma ChE inhibition with
time post-exposure (the opposite of what would be expected). However, the standard
deviation for the time-point groups is fairly large and the same trend is not observed in
the brain ChE activity in these same animals, therefore, the trend is probably not real
and is most likely the result of wide individual variation in plasma ChE activity.
The hemoglobin adduct half-life calculated of 20.6 days from our time-course data
is consistent with the half-life of rat erythrocytes in studies conducted by Noble and
Rothstein, 1986 and Neumann et al., 1993.46
The loss of radioactivity from erythrocytes and hemoglobin from 3 to 22 days
post-exposure is consistent with the kinetics of erythrocyte turnover. Our time-course
data fit the hemoglobin adduct removal model well, indicating the adduct is stable and
removed according to the expected erythrocyte kinetics.
Based on estimates of the total blood volume [64 mL/kg body weight (Schalm,
1986)] and total hemoglobin content [146 mg/mL blood (Schalm 1986)] of the rats,
we estimate that 0.36, 0.39, 0.33, and 0.31% of the original radioactivity administered
was recovered in the erythrocytes 3, 11, 15, and 22 days, respectively, after
administration. Approximately 0.49, 0.43, 0.39, and 0.32% of the original
radioactivity administered was recovered in the hemoglobin 3, 11, 15, and 22 days,
respectively, after administration, (Table 2.3). Therefore, 118% +/- 18 % of the
radioactivity recovered in the erythrocytes is associated with hemoglobin. This value
is based on estimates of the total blood volume and total hemoglobin content of the
animals and is subject to the error associated with these estimates. The percentage of
radioactivity associated with erythrocytes and hemoglobin reported here is consistent
with the finding of less than 1% of original radioactivity associated with erythrocytes
16 days after administration of [14C]AZM reported by others (Watson, 1992).47
Table 2.3 [14C]AZM binding efficiency with erythrocytes and hemoglobin
Sample collection
times
(days post-
exposure)a
Rat #Erythrocyte %
Doseb
Hemoglobin %
Dose`
% Dose Ratio
(hemoglobin/erythrocyte)
3 1 0.29 0.49 1.69
2 0.42 0.55 1.31
3 0.36 0.44 1.22
Ave. 0.36 Ave. 0.49
11 4 0.38 0.42 1.11
5 0.40 0.45 1.13
6 0.39 0.43 1.10
Ave. 0.39 Ave. 0.43
15 7 0.33 0.4 1.21
8 0.32 0.37 1.16
9 0.35 0.4 1.14
Ave. 0.33 Ave. 0.39
22 10 0.29 0.32 1.10
11 0.33 0.35 1.06
12 0.31 0.30 .97
Ave. 0.31 Ave. 0.32
Ave. 1.18 +/- 0.18
a[14C]AZM (3.0 mg/kg )
bErythrocyte % Dose = percentage of total dose associated with total erythrocytes
`Hemoglobin % Dose = percentage of total dose associated with total hemoglobin
The radioactivity associated with the hemoglobin could be due to metabolic
incorporation (Stevens et al., 1992) or covalently-bound adduct. Metabolic
incorporation is unlikely because the labeled carbon is in the benzene ring of AZM, a
stable structure unlikely to be completely metabolized.
We measured only radioactivity present in the samples; therefore, we cannot report
structural information about the AZM hemoglobin adduct. We are currently working
to identify the structure and location of the AZM hemoglobin adduct.48
The data from this experiment support our hypothesis that a metabolite of AZM
forms a hemoglobin adduct and may be useful as a biomarker of occupational AZM
exposure.
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Chapter 3
Analysis of Rat Hemoglobin Exposed to [I4C]Azinphos-methyl In Vivo
Bonnie J. Bailey and Jeff J. Jenkins50
Introduction
U.S. growers commonly use azinphos-methyl (AZM), an organophosphate
insecticide, on a variety of crops, which include cotton, apples, pears, sugar cane, and
cranberries. Each year, growers apply more than 1 million pounds to crops (Schreiber,
1997). Agricultural laborers who work in treated fields are frequently exposed to AZM
(Drevenkar et al., 1991; McCurdy et al., 1994). Acute AZM exposure in humans is
generally monitored by measuring plasma, erythrocyte, or whole blood cholinesterase
inhibition. Wide individual variation in blood cholinesterase activity requires pre-
exposure testing and limits its use as a quantitative biomarker of internal dose,
especially at low exposure levels (Sanz et al., 1991; Brock and Brock, 1993).
Organophosphate exposure can also be monitored by the presence of dialkylphosphate
metabolites in urine (Drevenkar et al., 1991; McCurdy et al., 1994). While this method
can detect low-level exposure, the rapid elimination of urinary dialkylphosphate
metabolites makes them useful for assessing only recent exposures, i.e., less than 48
hours (McCurdy et al., 1994). Neither method (enzyme inhibition or urine analysis)
detect AZM specifically.
A hemoglobin adduct that is specific for AZM exposure would be more useful
than cholinesterase or urinary metabolites for monitoring chronic AZM exposure
(Schnell, 1994). Adducts with hemoglobin are useful biomarkers of long-term
exposure because hemoglobin's long biological lifetime (120 days in humans) results
in dose-dependent accumulation of adducts to steady-state levels (Skipper and51
Tannenbaum, 1990). Hemoglobin adducts have been identified for a number of
pesticides or their metabolites including pentachlorophenol (Waidyanatha et al.,
1996), linuron (Sabbioni and Neumann, 1990), ethylenebisdithiocarbamates (Pastorelli
et al., 1995), and the organophosphate insecticide dichlorvos (Segerback and
Ehrenberg, 1981)We previously reported a dose-dependent and stable association of
radioactivity with rat hemoglobin following in vivo treatment with [14C]azinphos-
methyl ([14C]AZM) at doses that did not cause cholinesterase inhibition (Bailey and
Jenkins, 2000), which indicated the presence of an azinphos-methyl hemoglobin
adduct.
In the experiment reported here, we used HPLC, liquid scintillation spectrometry
(LSC) and mass spectrometry in an effort to determine the identity and binding site of
the putative AZM hemoglobin adduct. In order to develop analytical methods for
detecting the adduct it is important to identify the target protein(s) and the target
site(s) on the protein(s). Mass spectrometry has proved to be a useful tool in
identifying the nature and location of hemoglobin adducts on intact adducted proteins
(Farmer and Sweetman, 1995).
Materials and Methods
Materials
[14C]AZM (ring labeled, 92.99%pure, specific acitivity 46.9 mCi/mmol,
radiochemical purity 92.99 %) was provided by Bayer, Corp., Stillwell, Kansas;52
acetone, glass distilled; corn oil, Mazola 100% pure; Sprague-Dawley rats were from
Simonson, Gilroy, California; diet, Harlan Takled Rodent Diet; Complete Counting
Cocktail 3a70B, Research Products International Corp., Mount Prospect, Illinois;
glacial acetic acid, J.T. Baker; benzoyl peroxide, Sigma, St. Louis, Missouri, 70%
pure (remainder water); toluene, Burdick and Jackson Laboratories, Inc., Muskegon,
Michigan, gas chromatography grade; 5,5'-dithiobis-2-nitrobenzoic acid (DTNB),
Sigma; aectylthiocholine iodide (ATCh substrate), Sigma; tetraisopropylphosoramide
(iso-OMPA), Sigma; phosphate buffer, Sigma; 96-well plates, Corning, cat. no.
25880-96; Sigma Diagnostics Total Hemoglobin, Procedure No. 525, Sigma, St.
Louis, Missouri.
Animals
We housed 11 male Sprague Dawley rats (240-266 g at time of treatment) in clear
plastic "shoebox" style cages with wire lids, 2 or 3 animals per cage with pine
shavings for bedding. Animals were acclimated for 4 days prior to treatment. They
were housed in a climate and light controlled facility (22 +/- 2 °C, with a 12 hour
light/dark cycle, 50 +/- 10% humidity). Diet consisted of Harlan Takled Rodent Diet
(pellets). Animals had free access to food and water during the 4 days prior to
treatment. Animals were placed on a moderately restricted diet (Keenan et al., 1998)
from the time of treatment until sacrifice (7 days post-exposure). Ad libitum feeding
is a source of variation in studies. Moderate dietary restriction is recommended by
FDA's National Center for Toxicological Research and the National Research Council53
to reduce this source of variation (Keenan et al., 1998). Animals had free access to
water at all times.
Each rat received a single dose of [14C]azinphos-methyl ([14C]AZM). Treatment
groups were given a dose of 0, 3, 6 or 9 mg/kg [14C]AZM administered by gavage
with corn oil as a vehicle. [14C]AZM was dissolved in acetone (1% v/v of final gavage
solution) and then mixed with corn oil. Control animals received corn oil with 1%
(v/v) acetone. There were three animals in the control, 3 mg/kg, and 6 mg/kg treatment
groups and 2 animals in the 9 mg/kg treatment group. Gavage solution was prepared
fresh the day before administration and stored at 4 °C until use. Gavage solution was
analyzed by radiometric HPLC to confirm the AZM concentration prior to
administration.
Intermediate Blood Draws
Intermediate blood samples were collected at 24 hours, 3, and 5 days post-
exposure from the saphenous vein (located just above the ankle on the hind legs). The
blood collection method of Hem et al. (1998) was used. Intermediate blood samples
were collected into 370 pi heparinized capillary tubes, transferred immediately to
heparinized vacutainers, and stored at 4 °C until processing.54
Sacrifice and Terminal Blood Collection
Animals were sacrificed 7 days post-exposure. Animals were anesthetized with
CO2 prior to collecting blood (-5 mL) from the vena cava. Blood was collected into a
heparinized syringe and transferred immediately to a heparinized vacutainer. Animals
were killed by cervical dislocation. Blood samples were kept cold (-4 °C) until
processing. Brains were collected, placed in 3 mL cryotubes, frozen in liquid nitrogen,
and stored at -80 °C until analysis. All animal-use procedures were in strict accordance
with the National Institutes of Health Guide for the Care and Use of Laboratory
Animals and were approved by the Animal Care Committee of Oregon State
University.
Hemoglobin Isolation
Blood samples collected at sacrifice were kept cold (4 °C) until centrifugation.
An aliquot (50 til) of whole blood was removed from each sample for LSC prior to
centrifugation at 2,000 rpm for 5 minutes to separate erythrocytes from plasma.
Plasma samples were placed in microcentrifuge tubes and stored at -80 °C until
analysis. Erythrocytes were washed with isotonic saline (0.9% sodium chloride) 3
times, resuspended in one volume of saline and stored at -20°C. Erythrocyte
samples were thawed on ice and hemoglobin was isolated using the Antonini and
Brunori method (1971) with minor modifications. Briefly, this involved
centrifuging and discarding the supernatant of the erythrocyte samples, the
erythrocytes were lysed by the addition of three volumes of cold distilled water55
and allowed to stand for 30 min at 4 °C. Membrane proteins were precipitated by
adding saturated ammonium sulfate and allowing the mixture to stand for 45 min.
The lysate was centrifuged at 10,000g for 30 min on a Sorvall centrifuge (4 °C),
after which aliquots of the clear supernatant (hemoglobin solution) were
transferred to 1.5 mL microcentrifuge tubes. The hemoglobin solution was stored
at -20 °C until analysis. Hemoglobin concentration of the solutions was measured
by optical density at 540 nm, using Sigma Diagnostics Total Hemoglobin Kit, cat.
no. 525-A.
Cholinesterase Activity in Brain and Plasma
Whole brains were thawed on ice and homogenized on ice in a 1% Triton X-200
sodium phosphate buffer (pH 8) with a final dilution of 1:25 (volume:volume).
Aliquots (30 fiL) were removed and analyzed for acetylcholinesterase activity by the
Ellman method modified for microtiter plates (Wilson et al., 1996a). Plasma was
thawed on ice and 30 IAL analyzed for total cholinesterase activity by the Ellman
method as modified for microtiter plates (Wilson et al., 1996a). Rat plasma contains
50:50 AChE (E.C. 3.1.1.7): butyrlylcholinesterase (BChE) (E.C.3.1.1.8) (Traina and
Serpeitri, 1984), whereas brain tissue contains acetylcholinesterase only. Tissues
collected at each time point were assayed on the same day. The assay was adapted for
use with a microtiter plate reader (SpectraMAX 250 by Molecular Devices with
SOFTmax Pro software). The tissue samples were placed in microtiter plates in
triplicate. DTNB (final concentration = 0.32 mM) and 50 µL 0.1 M sodium phosphate56
buffer (pH 8) were added. The plates were preincubated at room temperature for 5
min. After preincubation, the ATCh substrate was added (final concentration = 1.0
mM), and the volume was brought up to 320 ilL with 0.1 M sodium phosphate buffer
(pH 8). Each plate was run with substrate and tissue blanks. The samples were read
kinetically for 5 min, during which time 28 separate absorbance readings were taken
for calculating the mean change in mOD (millioptical density)/min. The assay was run
at room temperature (-25 °C).
Solvent Extraction to Test for Covalent Binding
Aliquots (1m1) of hemoglobin solutions (from blood collected at sacrifice 7 days
post-exposure from treated and control animals), prepared as described above, were
extracted with a series of organic solvents to test for covalent binding of the
hemoglobin associated radioactive compound. Hemoglobin was precipitated by adding
4 ml ethanol dropwise while stirring. The precipitated hemoglobin was extracted 4
times, one time each with 4 ml of the following solvents in the order of: ethanol/water
(8:2), ethanol, ethanol/ether (1:3), and ether. The extracted hemoglobin samples were
dried over Dri-Rite in a dessicator and then stored at 20 °C. The extraction solutions
were stored at 4 °C until analysis.
LSC of Whole Blood and Unextracted Hemoglobin Samples
Aliquots (50111) of whole blood (collected 24 hrs, 3, 5, and 7 days post-exposure)
and unextracted hemoglobin solutions (200 [it) (collected 7 days post-exposure) were57
placed in 20 mL liquid scintillation vials and prepared for liquid scintillation
spectrometry using the protocol for NCS-II tissue solubilizer (Amersham Life
Sciences Product Data Sheet, 1992). NCS-II tissue solubilizer (1mL) was added to
each vial, mixed, and vials placed in a 50 °C water bath for 30 min. Vials were
removed from the water bath and placed in a 37 °C incubator overnight. The following
day, a decolorizing solution of benzoyl peroxide was prepared. Benzoyl peroxide (1 g)
was placed in a flask and 5 mL toluene added. The solution was heated to 60 °C for 10
min, cooled to room temperature, and filtered. Benzoyl peroxide solution (400 IlL)
was added to each sample vial , the vials were mixed, and then placed in a 50 °C water
bath for 30 min. After removing vials from the water bath and allowing them to cool
to room temperature, the pH of each vial was checked using pH paper. Counting
efficiency is maximized when the pH is between 6-7. If the pH was too high, 10 IAL
aliquots of glacial acetic acid were added until the pH was 6-7. No more than 20 IAL of
glacial acetic acid was required to adjust the pH. Complete Counting Cocktail (18 mL)
was added to each vial. Vials were inverted several times to mix and placed in the dark
for about 4 days to exclude light and reduce chemiluminescence prior to counting the
samples in a Packard Tri-Carb Liquid Scintillation Analyzer (model 1900CA).
LSC of Extracted Hemoglobin
Extracted hemoglobin samples (-5 mg) (from blood collected 7 days post-
exposure) were dissolved by adding 101A1 acetonitrile and then bringing the solution to
a final volume of 1 ml with milliQ water. Samples were vortexed, sonicated for 1 hr58
and kept at room temperature overnight. To remove undissolved hemoglobin, samples
were filtered using a 0.2 gm microcentrifuge tube filter (cellulose acetate cat. no. 352-
112 PGC Scientific)and centrifuged at 10,000g for 5 min. The hemoglobin
concentration of the filtered solution was measured using Sigma Diagnostics Total
Hemoglobin Kit, cat. no. 525-A.
LSC of Hemoglobin Extract Solutions
Hemoglobin extract solutions were analyzed by LSC. Complete Counting Cocktail
scintillant (16 ml) was added to 3.5 ml of the hemoglobin extract solution. The vials
were inverted several times to mix, and then placed in the liquid scintillation
spectrometer for analysis.
HPLC of Hemoglobin
The method of Schroeder et al. (1985) was used (with slight modifications) for
hemoglobin analysis. A sample of 20 pl of 30 mg/mL hemoglobin was injected onto
a reversed-phase Vydac C4 column (214TP, cat. #214TP54, 25 cm x 4.6 mm, ID Sum)
was used. Mobile phase was composed of A: 80% H2O, 20% ACN, 0.1%TFA; B:
40% H2O, 60% ACN, 0.1% TFA. A gradient of 35 to 56.5 % in 60 min, then 80% in
2 min was used with a flow rate of 1 mL/min. A UV detector was used at a
wavelength of 280 nm.59
Fraction Collection/LSC
One minute fractions (1 mL each) of HPLC effluent were collected using an
automated fraction collector and analyzed by LSC. Fractions were collected into glass
test tubes and transferred by pipette to liquid scintillation vials. Complete Counting
Cocktail scintillant (18 ml) was added, the vials were inverted several times to mix,
and then samples were placed on the liquid scintillation spectrometer for analysis.
LC-MS
HPLC fractions of unextracted hemoglobin samples (from blood collected 7 days
post-exposure, from animals treated with 9 mg/kg [14C]AZM) were analyzed on a
LCQ-MS, Classic. The LCQ-MS is a Thermoquest iontrap mass spectrometer. The LC
system consisted of a Perkin Elmer ABI 140 B syring pump, a Rheodyne 8125
injector with a 5 pl loop, and a 0.32 mm x 10 cm, 5 pm particle Vydac 238 C918)
monomer column. The solvents were A: water and B: acetonitrile each with 0.1%
acetic acid and 0.01% TFA, which were delivered at 5 pL/min isocratically, at 80% B.
Conditions were optimized for 5 pl/min, with a heated capillary (temp. 180 °C) and
the needle voltage at 4500V in positive ion mode. Prior to hemoglobin analysis
instrument response was determined with a standard peptide solution.
Based on the LSC results, HPLC fractions 52-56 were collected and combined
(total volume of 30 mL). A total of six runs were collected and combined. The
acetonitrile was blown off under a gentle stream of nitrogen, reducing the volume to60
about 15 mL. The sample was then freeze-dried to remove the water. Prior to mass
spectrometric analysis the sample was redissolved in 100 [11MilliQ water.
Results
Hemoglobin was isolated from blood samples collected at sacrifice (7 days post-
exposure) only as there was insufficient blood in the intermediate samples (24 hr, 3,
and 5 days post-exposure) for hemoglobin isolation. The intermediate blood samples
were analyzed for plasma cholinesterase and an aliquot of whole blood was analyzed
by LSC to determine the amount of radioactivity.
Cholinesterase
At two hours post-exposure animals in the control group and lowest treatment
group (3 mg/kg [I4C]AZM) showed no signs of cholinesterase inhibition. The animals
in the 6 mg/kg [14c].AZm group showed slight signs and animals in the 9 mg/kg
[14C]AZM group showed clear signs of cholinesterase inhibition including labored
breathing, trembling, and subdued activity. By 4 hours post-exposure only the highest
treatment group showed signs of cholinesterase inhibition and by 8 hours post-
exposure none of the animals showed signs of cholinesterase inhibition. None of the
animals died as a result of [I4C]AZM treatment.
Plasma cholinesterase data are summarized in Table 3.1. Data are shown as
percent control. The highest plasma cholinesterase depression was seen at 24 hours61
post-exposure in the highest treatment group (9 mg/kg [14C]AZM) with 57.6% of
control activity. There was a clear dose response in the plasma cholinesterase activity
at 24 hrs post-exposure. Although there was considerable variation among replicates,
the plasma cholinesterase levels appear to recover over the course of the 7-day
experiment, returning to control levels by 7 days post-exposure.
Table 3.1. Summary of rat plasma cholinesterase following treatment with [14gAZM.
Data presented as percent control (SD).
Treat-
ment
(mg/kg)
Time Post-Exposure
24 hours 3 days 5 days 7 days
Ave Ave Ave Ave
3 68.882.3 (16)79.688.2(12.1 )83.5 94.1(15.6) 91.4 103.5(10.7)
3 78.2 96.7 86.7 112
3 100 N/A 112 107
6 71.9 71.2(1) N/A 81.1 116 116 97.2 115(24.6)
6 70.5 N/A N/A 132
6 N/A 81.1 N/A N/A
9 N/A 57.6 89.489.6(0.28) N/A N/A 106 106
9 57.6 89.8 N/A N/A
SD = standard deviation
N/A = insufficient plasma for analysis
Brain cholinesterase data are summarized in Table 3.2. Data are shown as percent
control. Brain cholinesterase activity at sacrifice (7 days post-exposure) had not
completely recovered to control levels. Average brain cholinesterase activity ranged
from 79.7 to 91.3 percent control for the 9 mg/kg and 3 mg/kg treatment groups,
respectively.62
Table 3.2. Summary of rat brain cholinesterase 7 days post-exposure following
treatment with [14C]AZM. Data presented as percent control.
TreatmentBrain CholinesteraseAve
3 mg/kg 94.0 91.3(2.4)
3 mg/kg 89.7
3 mg/kg 90.1
6 mg/kg 85.1 87.7(2.9)
6 mg/kg 87.1
6 mg/kg 90.0
9 mg/kg 85.4 79.7(8.1)
9 mg/kg 74.0
LSC of Whole Blood
As shown in Fig. 3.1, LSC of whole blood was consistent with our previous results
of a dose-dependent association of radioactivity with erythrocytes and hemoglobin
(Bailey and Jenkins, 2000). The data were fitted with one-phase exponential decay
curves. All the curves had R2 values >0.95.
Solvent Extraction to Test for Covalent Binding
To test for covalent binding of the adduct, hemoglobin samples (from blood collected
at sacrifice) were extracted with ethanol/water (8:2), ethanol, ethanol/ether (1:3), and
ether. We measured the radioactivity in unextracted hemoglobin and extracted
hemoglobin samples by LSC. We measured the amount of hemoglobin in both
unextracted and extracted samples using the Sigma Diagnostics Kit and expressed the
radioactivity in dpm/mg hemoglobin. We compared the dpm/mg hemoglobin in the
extracted hemoglobin to the unextracted hemoglobin and found greater than 100%63
(118 to 143%) recovery of the radioactivity (average of 132%, n = 4). The greater than
100% recovery and high variability is probably due to the low activity in the extracted
samples (200 to 750 dpm total/sample) resulting in over-estimation of the radioactivity
content of the samples.
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Figure 3.1. Radioactivity in whole blood shows dose-dependent association of
radioactivity with whole blood and gradual decline over the 7-day experiment.
Less than 1% of the total radioactivity in the hemoglobin was found in the extract
solutions. The fact that we were unable to remove a significant amount of radioactivity
from the hemoglobin by extraction and the high recovery of radioactivity in the64
hemoglobin after extraction indicate that the radioactive moiety is covalently bound to
hemoglobin.
Ratio of [14CJAZM to Hemoglobin
Based on LSC of unextracted hemoglobin isolated from blood samples collected at
sacrifice from rats treated with 9 mg/kg [14C]AZM, we estimate approximately 1:1000
moles of [14C]AZM to moles hemoglobin in our samples (see Table 3.3) or 12.5
nmol AZM/g hemoglobin. This is an approximation as the radioactivity could
represent AZM or a metabolite or both.
Table 3.3 Covalent bindind analysis of hemoglobin from [14C]AZM treated rats.
MethodConc.
(mg/m1)
Hemoglobin
counted (mmol)
Radioactivity
(dpm)
Specific
Activity
(dpm/mmol)
AZM
(mmole)
AZM/ hemo-
globin
(mol/mol)
OD 28.4 8.90E-05 7612 8.60E+07 7.30E-08 0.0008
Hemoglobin was dissolved in water and filtered. The concentration was determined by absorbance at
540 nm. An aliquot of hemoglobin solution was used to determine the radioactivity using LSC. The
AZM to hemoglobin ratio was calculated based on the results.
Location of Adduct
Hemoglobin is composed of 4 proteins (2 alpha globins, 2 beta globins) and heme.
There are 2 forms of the alpha globin (alpha' and alpha2) and 4 forms of the beta
globin (beta 1-4). To separate the heme, alpha globins, and beta globins unextracted
hemoglobin samples isolated from blood collected at sacrifice (7 days post-exposure)
were analyzed on reversed-phase HPLC with UV detection. One-minute fractions65
were collected and analyzed by LSC. Fig. 3.2a shows the LSC results of the fraction
collection. Fig. 3.2b shows the UV chromatogram. Peak 1 is heme, peak 2 is alpha',
peak 3 is alpha2, peak 4 is beta1, and peaks 5 and 6 (which are not completely
resolved) contain beta2_4. The peak identities are based on elution order (Schroeder et
al., 1985) and our own mass spectrometric analysis of the peaks (data not shown). We
found a single radioactive peak, which eluted at the trailing edge of the last beta chain,
with a retention time of 52 minutes (marked with an arrow on Fig. 3.2b). Table 3.4
summarizes the HPLC and fraction collection data.
Table 3.4. Summary of HPLC/fraction collection/LSC of hemoglobin from rats 7
days post-exposure following treatment with 9 mg/kg [14C]AZM.
HPLC Peak
Number
Fraction Number Radioactivity
Detected?
Identity Based on
Elution Order
2 38 No alpha
4 46 No beta
5 48 Yes beta
6 52 Yes beta
54 Yes beta
none 56 Yes
none 59 No ?225
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Figure 3.2a Radioactivity in hemoglobin HPLC fractions. Fractions were collected at
on minute intervals
ICI20 aa 4050 GO TO80
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Figure 3.2b. HPLC Chromatogram of hemoglobin. Peak 1=heme, peak 2= alphai,
peak 3=alpha2, peak4betal, peak 5 and 6 (unresolved)=beta2_4. The retention time of
the radioactive peak is indicated by an arrow.67
Identity of Adduct: HPLC fractions of hemoglobin from blood collected at
sacrifice (7 days post-exposure) were concentrated and analyzed by LCQ/MS. We
found a single protein with a mass of 15849.4 which is consistent with that of the beta3
chain (15850.57 +/- 1.47) (Ferranti et al., 1993) in the radioactive fraction. We
detected no other proteins in the radioactive fraction. We were unable to identify the
adduct from this data, since the only protein detected shows no evidence of adduction
(ie additional mass due to adduct). AZM has a mass of 317. Some of its known
metabolites, AZM-oxon, mercaptomethylbenzazimide, and desmethyl isoazinphos-
methyl have masses of 301, 293, and 303, respectively.
We estimated the adducted protein content in the concentrated samples based on
the radioactivity in the hemoglobin samples and the following assumptions: 1) adduct
is bound to beta3 protein, 2) adduct is AZM, 3) one molecule of AZM/molecule of
beta3, 4) no loss of sample during HPLC, fraction collection, concentration, and MS.
Based on these assumptions we estimated an adducted protein content of 3 pmole in
the sample we analyzed by LCQ-MS.
Discussion
The cholinesterase data indicate that the animals received an AZM dose large
enough to cause cholinergic crisis in the 9.0 mg/kg treatment group. The plasma
cholinesterase activity in this group returned to normal within 7 days. The brain
cholinesterase activity was 79.7% of controls at 7 days post-exposure in the 9.0 mg/kg68
treatment group. Plasma cholinesterase activity in the 3 and 6 mg/kg groups were
normal by 7 days post-exposure, whereas the brain cholinesterase activity in these
groups remained depressed at 7 days post-exposure. Plasma cholinesterase is not an
accurate biomarker of AZM exposure at 7 days or more post-exposure in these
animals, since the brain cholinesterase activity was still inhibited, but the plasma
cholinesterase showed normal activity. In humans, plasma cholinesterase is an
accurate biomarker of exposure up to about 30 days post-exposure.
The solvent extraction data support our hypothesis of a covalently bound AZM or
a metabolite adduct to hemoglobin, since we were unable to remove radioactivity from
the hemoglobin (from blood collected 7 days post-exposure ) by solvent extraction.
The HPLC/fraction collection/LSC data are consistent with an adduct on one of
the beta globin chains. The presence of a single radioactive peak at a retention time of
52 minutes is consistent with the adduct being bound to one of the beta globin chains.
The last beta globin chain elutes between 49 and 56 minutes. The presence of an
adduct, increases the mass and tends to change the charge on the protein, and therefore
might make the adducted globin elute slightly later than the unmodified globin
(Schnell, 1993; Noort et al., 1996)). The adduct could be bound to any of the beta
chains (beta 1_4) or even one of the alpha chains. Because the beta protein has been
identified as a common adduction site by others (Schnell, 1993) and the radioactive
peak elutes at the trailing edge of the beta chains it is likely that the adduct is bound to
one of the beta proteins.69
The lack of supporting mass spectrometry data could be due to the low
concentration of adducted globin in the sample. There may not be enough adducted
globin to detect by mass spectrometry of intact globin. We estimated 3 pmol of
adducted protein in our sample, however this was based on a number of assumptions.
The actual amount of adducted protein may have been less the 1 pmol. The detection
limit of the LCQ-MS is 1pmol of protein. The LCQ-MS may not be sensitive enough
to detect the adducted protein.
Conclusions
Data from this experiment support our hypothesis of an AZM hemoglobin adduct
and confirm our previous results of dose-dependent binding of the radioactive AZM
moiety to globin. We found evidence that indicates the adduct may be bound to one of
the beta globin chains, but were unable to determine the identity of the adduct.
Collecting blood samples at an earlier time (ie 24 hours post-exposure) might increase
the adducted globin chain levels to a detectable level. Increasing the dose to increase
detectability is not feasable as the animals receiving 9 mg/kg dose had significant
cholinesterase inhibition as evidenced by labored breathing and trembling two hours
post-exposure. A higher dose would likely result in mortality (the AZM oral LD50 in
rats is reported as 4-20 mg/kg).
Future research needs include identification of the adduct binding site and the
identity of the adduct by treating the hemoglobin with a protease (trypsin and/or V8)70
followed by HPLC and MS (Birt et al., 1998 and Li et al., 1999). Immunoprecipitation
or concentration methods may also be used. Once the adduct has been characterized
by its molecular weight and binding site, efforts could be made to improve analytical
techniques in order to make detection in exposed workers possible.
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Chapter 4
Evidence for a Heme Adduct Generated by In Vitro Incubation of Azinphos-methyl
with Rat Hemoglobin in a Liver Microsome System
Bonnie J. Bailey and Jeff J. Jenkins72
Introduction
Azinphos-methyl (AZM) is an organophosphate insecticide commonly used in
U.S. agriculture production. Agricultural laborers who work in treated fields are
frequently exposed to AZM. Acute AZM exposure can be monitored by measuring
cholinesterase inhibition in the blood or by the presence of an AZM metabolite in the
urine. Both methods have limitations, which have led us to investigate another method
of detecting exposure. Our research has focused on determining whether AZM
association with hemoglobin could be used as a biomarker of exposure. Previous work
showed a dose-dependent and stable association of [14C]AZM with rat erythrocytes
and hemoglobin (Bailey and Jenkins, 2000) and evidence of an AZM hemoglobin
adduct bound to the beta protein of hemoglobin (Chapter 2). We were unable to
determine the identity and binding site of the AZM hemoglobin adduct, because the
adducted hemoglobin concentration was likely below the detection limit of the mass
spectrometer used for analysis (an LCQ-MS). In order to increase the concentration of
adducted hemoglobin we, therefore, incubated AZM with hemoglobin in a rat liver
microsome system, which showed evidence of an AZM adduct to heme.
Liver microsomes, liver homogenates, and perfused livers have been shown to
produce a number of AZM metabolites. Lin et al. (1980) incubated AZM (MW = 317)
with rat liver homogenates. The incubation mixture was extracted with ethyl acetate
and the extract analyzed by HPLC and mass spectrometry. They identified two AZM
metabolites, AZM-oxon (MW = 301) and benzazimide (MW = 147). Sultatos et al.73
(1987) reported that in perfused mice livers, 40.1 to 47.8% of AZM introduced was
recovered unchanged in the effluent; 4.0 to 5.2% was AZM-oxon, and 47.1 to 60.1%
were other (unidentified) metabolites. Motoyama and Dauterman (1972) report
transformation of AZM to AZM-oxon was catalyzed by P450(s) in the microsomal
fraction of rat liver homogenates. The same enzyme system caused degradation of
AZM and AZM-oxon to form mercaptomethylbenzazimide (MW = 193) and
dimethylphosphorothioic acid (MW = 142).
In vivo experiments with AZM have identified several enzymes that produce
AZM. metabolites. Watson (1992) reported that in rats AZM was biotransformed in
vivo by cytochrome P450(s) and GSH transferase. He stated that P450(s) catalyzed the
formation of AZM-oxon as well as mercaptomethyl benzazimide, which then was
hydrolyzed to benzazimide and methylated to methythiomethylbenzazmide. Watson
(1992) also reported that AZM was transformed in vivo in rats to glutathione
conjugates; however, Sultatos and Woods (1988) found that glutathione-mediated
reactions of AZM did not occur to a significant degree in vivo in mice. A schematic of
AZM metabolism in rats is shown in Figure 1.1. No reports in the published literature
were found in which hemoglobin was incubated with AZM and liver microsomes or
liver homogenates. Because several of the primary metabolites of AZM are produced
by cytochrome P450(s), present in liver microsomes under conditions where AZM
would also be present, we felt that microsomal incubation of hemoglobin with AZM
was likely to produce the hemoglobin adduct that we observed in vivo.74
Materials and Methods
Chemicals
Azinphos-methyl was provided by Bayer, Corp., Stillwell, Kansas; Sprague-
Dawley rats were from Simonson, Gilroy, California The diet was Harlan Takled
Rodent Diet. The lyophilized rat hemoglobin, Trizma Base (Sigma T-1503),
monobasic potassium phosphate (Sigma P-5379), dibasic potassium phosphate (Sigma
P-5504), glycerol (Sigma G-7757), and NADPH were from Sigma, St. Louis,
Missouri. The glacial acetic acid (Ma llinckrodt UN2789), EDTA, and acetonitrile
were from Ma llinckrodt Baker, Inc. Paris, Kentucky. The KCL (Fisher P217-500) and
TFA were from Fisher, Fairlawn, New Jersey. The Coomassie Plus Protein Assay
Reagent Kit (Prod. No. 23236) was from Pierce, Rockford, Illinois.
Animals
Male Sprague-Dawley rats (244-320 g at time of sacrifice) were individually
housed in stainless steel metabolism cages in a climate- and light-controlled facility
(22 +/- 2 °C, with a 12-hour light/dark cycle, and 50 +/- 10% humidity). Diet consisted
of Harlan Takled Rodent Diet (pellets). Animals had free access to food and water at
all times. They were not induced or starved prior to sacrifice. Animalswere
anesthetized with CO2 prior to tissue collection and killed by cervical dislocation.
Liver tissue (-3 g) was placed in a 3.6 ml cryotube and immediately frozen in liquid
nitrogen. Liver samples were stored at 80 °C until preparation of microsomes. All75
animal-use procedures were in strict accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the Animal
Care Committee of Oregon State University.
Liver microsomes
Microsomes were prepared by differential centrifugation as described in Williams
et al. (1989). The washed microsomes were resupsended in 0.1 M potassium
phosphate buffer, pH 7.4, containing 20% glycerol and 1 mM EDTA, and frozen at
80 °C before use. Protein and P450 contents of liver microsomes were estimated by
the methods of Pierce Coomassie Plus Protein Assay Reagent Kit (1999) and Omura
and Sato (1964), respectively.
Incubation
The incubation mixture consisted of 0.32 nmol of microsomal P450, 50 mM Tris-
HC1, pH 7.4, 1 mM magnesium chloride, 5 mM potassium chloride, 1.0 mM NADPH,
1 mM AZM (dissolved in ethanol), and 1 mM lyophilized rat hemoglobin (33 mg) in a
total incubation volume of 0.5 mL (modified from Pastorelli et al., 1995).
The reaction was started by adding NADPH. The samples were incubated at 37 °C
for 60 min and incubations were terminated by chilling in ice. The hemoglobin was
separated from the microsomes by centrifugation at 48,000g for 30 min and stored at
80 °C until analysis. Samples were thawed at room temperature prior to analysis.76
ESI-MS
Hemoglobin was analyzed on a Perkin Elmer Sciex API III+ triple quadrupole
ionspray mass spectrometer (PE-Sciex, Thornhill, Ontario, Canada). The instrument
was calibrated in the positive mode with a mixture of polypropylene glycols. A
desalting cartridge was inserted just after the injection port, in place of the sample
loop. The salt trap was filled with acetonitrile (ACN) followed by the eluting solvent
(10% ACN, 0.1% TFA) before loading the sample. Then eluting solvent was injected
to remove salts before injecting the sample. The samples were introduced to the mass
spectrometer via pneumatically assisted electrospray (ionspray). The potential of the
ionspray needle was placed at 5000 V. The potential of the orifice leading into the
mass analyzer was maintained at 80 V in the positive ion-detection mode. The
nebulizer gas (air) was set to 42 psi, and the curtain gas (nitrogen) was set to 0.6
L/min. Prior to hemoglobin analysis, instrument response was determined with a
standard peptide solution. Mass spectra were obtained with: dwell time = 2 ms, step =
0.4 amu, pause = 5 ms, 54 scans, duration = 6.3 min. Approximately 5 scans were
summed to improve the signal-to-noise ratio.
Results
We found a mass and peak pattern consistent with AZM binding to the heme. A
peak with a mass of 933 (heme = 616 + AZM = 317) was observed. The 933 peak had
a pattern consistent with that of heme. That is, it was not part of a protein envelope
pattern. The 933 peak was a very sharp peak, much like the heme dimer (1231) peak77
(see Figure 4.1). The proteins present in the samples have masses consistent with
globin alphai and beta2 (see Table 4.1).
Table 4.1 Hemoglobin AZM Microsomal Incubation ESI/MS
ComponentExpected MassObserved MassDifference
alphai 15,197.39+/- 15,192.22 +/- 5.2
0.98 2.29
beta2 15,864.13+/- 15,874.18 +/- 10.5
2.73 7.21
heme 616 933.2 +/- 0.4 317.2
The 933 peak was present in all samples containing AZM and hemoglobin, even in
samples that did not contain microsomes or that did not contain NADPH (required for
an active microsome system). It was not present in samples containing hemoglobin
and microsomes, but no AZM (see Figure 4.2). The 933 peak was not present in
samples without AZM (see Figure 4.3).
Discussion
The results of this in vitro experiment suggest that microsomal enzymes are not
involved in AZM heme adduct formation. This finding is supported by the fact that the
933 peak was present in all samples containing AZM and hemoglobin, even samples
without microsomes or without NADPH (see Table 4.2).78
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Figure 4.1 Herne adduct (mw = 933.2) present in sample containing hemoglobin,
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Figure 4.2 Heme adduct (mw = 933.2) present in sample without an active microsome
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Figure 4.3 Heme adduct absent from sample without AZM, with hemoglobin and
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Table 4.2 Hemoglobin AZM microsome incubation conditions
AZMHemoglobinMicrosomesNADPH933 peak
detected?
no yes no no no
no yes yes yes no
yes yes yes no yes
yes yes yes yes yes
In spite of the limited structural information obtained by ESI/MS, we speculate on
a mechanism for the putative AZM-heme adduct formation. The mass difference
between the adducted heme and heme indicates the adducted molecule may be AZM.
This means AZM would have to be non-covalently bound to the heme, since any
covalent binding would reduce the mass of the AZM-heme complex. ESI/MS is a soft
ionization technique, which might preserve a noncovalent association. Drugs and other
xenobiotics have been found to non-covalently bind to hemoglobin (Tannenbaum and
Skipper, 1994). A common adduction site is the cysteine residue located at position 93
on the beta protein chain. The relatively high reactivity of this cysteine residue has
been attributed to its close proximity to the heme. The heme itself is not covalently
bound to the globin proteins of hemoglobin, but is held in place by specific
coordination with side groups on nearby amino acids in the globin. Further analysis of
the adducted heme using tandem mass spectrometry, which would fragment the ions,
would provide more structural information about the adducted molecule and might
clarify the adduction mechanism. Even assuming P450-like activity of the hemoglobin
(Mieyal and Starke, 1994), none of the expected AZM metabolites have a mass that83
could account for the observed heme adduct. The molecular structure of heme is
shown in Figure 4.4.
We found a few published reports of xenobiotic adduction to heme in vivo and in
vitro. Naylor et al. (1990) found benzo[a]pyrene adduction to heme was time
dependent. One day after administration of [3H]benzo[a]pyrene to mice, the heme
fraction of the hemoglobin contained most of the radioactivity. The radioactivity in the
heme fraction decreased to 9% of the total recovered radioactivity (from a high of
85%) by 38 days post-exposure. As the percent of radioactivity in the heme decreased,
the percent of radioactivity recovered in the globin increased to a high of 91% 38 days
post-exposure. Naylor et al. concluded that the benzo[a]pyrene heme adducts were
unstable. Lame et al. (1997) administered [3H]dehydromonocrotaline (a pyrrolizidine
alkaloid) to rats and found <2% of administered radioactivity associated with the heme
2 hours post-exposure, compared to 68.5% of the radioactivity associated with the
globin. Samples collected 4 and 24 hours post-exposure showed a similar amount of
radioactivity associated with the globin, but they did not report the amount of
radioactivity associated with the heme. Bakhtiar et al. (1997a) found evidence for a
heme adduct generated by in vitro reaction of 2,4,6-trinitrotoluene (TNT) with human
hemoglobin. They reported that the incubation and isolation of the adducted heme
products can be extremely sensitive to stoichiometry of the reactants, pH, temperature,
light, and the choice of solvent. They found a heme adduct only under reduced and
anaerobic conditions, indicating that the state of the heme is critical to formation of the
TNT adduct. Fruetel et al. (1994) found no heme adduction when dienochlor (a84
miticide) was incubated in vitro with glutathione-S-transferase and hemoglobins from
six mammalian species.
A hemoglobin molecule is composed of four protein chains (two alphas and two
betas) and four heme units. In vertebrates, hemoglobin functions to bind molecular
oxygen to its heme irons at the lungs and deliver it to the tissues and to bring the
carbon dioxide back to the lungs for removal (Dickerson and Geis, 1983). In vivo,
heme is generally in the reduced Fe2+ state in both the oxy and deoxy forms.
Lyophilized hemoglobin (which we used in our experiment) is predominantly
methemoglobin (in the oxidized Fe3+ state) because native hemoglobin is readily
oxidized in air.
The results of this experiment are not consistent with the results of our in vivo
experiments in which we found evidence of AZM (or a metabolite) binding to the beta
protein of hemoglobin in samples collected 7 days post-exposure (Chapter 2). Based
on the results of Naylor et al. (1990), it is possible that we might have found heme
adduction at an earlier time point. Bakhtiar et al. (1997b) found in vitro evidence of
TNT adduction to both the heme and the globin (alpha and beta proteins). It could be
that AZM (or a metabolite) binds to both the heme and globin in vivo. The in vivo
heme adduct may form at lower levels in vivo than in vitro based on the report of
Mieyal and Starke (1994), which could explain the difference between our in vivo and
our in vitro results. If a heme adduct was present in our in vivo samples, the adducted
molecule could have become detached from the heme during sample preparation or85
HPLC. The HPLC mobile phase (containing 0.1% TFA) had a pH of 2. Bakhtiar et al.
(1997a) noted that the TNT heme adduct was sensitive to pH. Our experiment was
conducted under aerobic and non-reduced conditions; therefore, the heme was in the
oxidized Fe3+ state. The state of the heme in vivo is reduced Fe2+, which could also
account for the difference between our in vitro and in vivo results.
Another difference between our in vivo and in vitro experiments, which could
account for the different results, is the ratio of AZM to hemoglobin. In our in vivo
experiment, we estimate an approximate 1:1000 ratio of AZM to hemoglobin in
samples collected 7 days post-exposure (Chapter 2). In our in vitro experiment
(reported here) we used equimolar concentrations of AZM to hemoglobin, which is a
much greater concentration than can be achieved in vivo.
Conclusions
Initial results of in vitro incubation of AZM with hemoglobin in a liver microsome
system showed evidence of an AZM adduct to heme. Liver microsome enzymes
appear not to be involved in the reaction because the adducted heme was seen in
samples without active microsome systems. These results are inconsistent with our
previous results in vivo, showing evidence of AZM (or a metabolite) adducted to the
beta protein of hemoglobin. Further experiments are needed to fully characterize the
AZM heme adduct, the conditions required for its formation, and to determine if it
could be used as a biomarker of AZM exposure.86
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Chapter 5
Summary
Bonnie J. Bailey88
As a result of my research on hemoglobin adducts of AZM I have found support
for our hypothesis that AZM or a metabolite forms an adduct to hemoglobin. The
results of in vivo experiments have shown:
1) dose-dependent association of radioactivity with hemoglobin following oral
administration of [14C]AZM to rats.
2) elimination of radioactivity from hemoglobin followed the expected elimination
kinetic of erythrocytes, indicating adduct stability.
3) evidence that the adduction site may be one of the beta chains of hemoglobin.
The results of in vitro experiments have shown evidence that the adduction site may
be the heme, instead of or in addition to, the globin of hemoglobin.
Further research is necessary to fully characterize the AZM hemoglobin adduct,
including the identity of the adducting compound and the in vivo adduction site. With
complete characterization of the adduct, efforts can be made to develop analytical
techniques for monitoring in human subjects.
Future experiments would include:
1) enzymatic digestion of hemoglobin from rats treated with AZM, followed by
immuno-affinity chromatography to concentrate the adducted peptides. ESI/MS
analysis of the peptides can be used to identify the adduct and the adduction site.
2) further in vitro experiments with AZM and hemoglobin to confirm our
preliminary in vitro findings of an AZM adduct to heme and to characterize the
conditions required for heme adduction.89
AZM will probably continue to be used for the near future because it is an
important tool for efficient agricultural production and there are no alternatives at
present to replace it. Concern over agricultural worker and general public exposure to
AZM is unlikely to dissipate, therefore, there will be continuing interest in monitoring
human exposure to AZM for risk assessment, and a continuing need for sensitive,
chemical specific monitoring methods.
Analytical techniques will continue to improve and detection limits will continue
to drop. This may make it possible to identify and detect the AZM hemoglobin adduct
of which I have found evidence in my research. AZM antibodies have been developed
by two groups, Mercader et al (1995) in Spain and Jones et al. (1995) in New Zealand.
AZM antibodies could be used to develop immuno-affinity chromatography, which
would aid in isolating the adducted hemoglobin or peptides from the non-adducted
molecules, thus improving sensitivity. Antibodies to AZM may also be used to
develop an ELISA-based detection method for the hemoglobin adduct, which could be
used for routine screening of agricultural workers.
Much of the early research on hemoglobin adducts has been conducted in vitro or
in laboratory animals. In vitro and laboratory studies are necessary to provide the
necessary background before proceeding to human in vivo studies. As the techniques
for analyzing hemoglobin adducts improve and as the knowledge base for hemoglobin
adduct chemistry and kinetics grows, more human monitoring studies will be possible.90
There has been a continuing increase in sophistication in the monitoring of human
exposure to xenobiotics from measuring concentrations of xenobiotics in
environmental media, to respirators, clothing, or dermal monitoring, to blood and
urine sampling for acute exposure, to biomarkers of chronic exposure, effects, and
susceptibility. These changes have been driven in part by a shift in concern from acute
to chronic exposures and in part by improvements in analytical techniques and
improved understanding of the mechanisms of actions and pharmicokinetics of
xenobiotics. I expect this increased interest in chronic health effects and sophistication
in detection methods will continue However, risk assessment is not only influenced by
improvements in exposure assessment. It is also influenced by politics and public
sentiment. The recent EPA position on chloroform in drinking water is an example of
science being overridden by politics and emotions. Pesticide use is a highly emotional
subject for many people. There are many people who sincerely believe that all
pesticides are bad and should never be used. Scientific data to the contrary will not
change their opinion. It is important for scientists to keep this in mind. Certainly,
scientific research on pesticide exposure is important, but in the final analysis many
people's feelings and values are incorporated into pesticide risk assessment and
management decisions.91
Chapter 6
Summary for Non-scientists
Bonnie J. Bailey92
I studied a pesticide called azinphos-methyl. It is used to kill insects on many
crops including apples, pears, cranberries, corn and shrubs.
I have tried to find a new method of measuring whether agricultural workers have
been exposed to azinphos-methyl, and if so, how much. Is it enough to make them
sick? People exposed to enough azinphos methyl may have a headache, upset
stomach, and difficulty breathing. If a person is exposed to a lot of azinphos-methyl
they can die.
Current methods for measuring exposure to azinphos-methyl include urine and
blood analysis. These methods have some limitations. The urine samples are only
useful if they are collected within 2 days of when a person comes in contact with
azinphos-methyl. The urine analysis does not detect exposure to only azinphos-
methyl. Other chemicals can be detected too, which makes it hard to tell exactly how
much azinphos-methyl the person was exposed to. The blood analysis measures a
chemical in the blood that is affected by azinphos-methyl. If a person comes in contact
with azinphos-methyl, there will be less of this chemical in their blood. But the
amount of this chemical varies a lot from person to person, so it is hard to tell if a low
measurement is normal for that person or if they have been exposed to azinphos-
methyl.
I tested the idea that azinphos-methyl or an azinphos-methyl breakdown product
might attach itself to hemoglobin. Hemoglobin is a chemical found in blood.93
Hemoglobin stays in the blood for 3-4 months before your body replaces it with new
hemoglobin. If azinphos-methyl or one of its breakdown products attaches itself to
hemoglobin, it could be detected for a long time after a person came in contact with
azinphos-methyl. This would be an improvement over urine analysis. Measuring
azinphos-methyl or one of its breakdown products attached to hemoglobin would tell
us how much azinphos-methyl a person was exposed to. It could not be confused with
exposure to other chemicals.
I treated rats with radioactive azinphos-methyl. I collected blood from the rats and
measured the radioactivity in the blood. I also isolated hemoglobin from the blood and
measured the radioactivity in the hemoglobin. I found a small amount of radioactivity
in the blood and the hemoglobin. This means that azinphos-methyl or one of its
breakdown products can be found in the hemoglobin.
I also did some experiments with azinphos-methyl and hemoglobin in a test tube.
When I mixed azinphos-methyl with hemoglobin I found evidence that azinphos-
methyl was attached to part of the hemoglobin.
I hope that with improvements in the methods for analyzing azinphos-methyl or its
breakdown products in hemoglobin that we will be able to use this method to tell if
workers have been exposed to azinphos-methyl. For now, there is more work to be
done before this method can be used in people.94
Chapter 7
Statement of Educational Philosophy
Bonnie J. Bailey95
In my many years as a student I have been privileged to have several excellent
teachers. I have also had the misfortune of having a few terrible teachers. My teachers,
the good ones and the bad ones, have had a huge influence on me. I don't know if my
teacher's realized how much what they did mattered (for better or worse). My own
experiences as a teacher have taught me that being a teacher is a lot harder than it
looks. I have spent a lot of time reflecting on the qualities of a good teacher.
My undergraduate degree is in science education, which included practical
teaching experience in junior and senior high school classrooms. Prior to entering
graduate school I worked for three years. My first job after completing my
undergraduate degree was as an education specialist at a zoo, where I presented
educational wildlife programs to people of all ages. Then, I worked for two years as a
substitute teacher filling in for elementary, junior high, and high school teachers in a
wide variety of subjects. While I was substitute teaching I worked part-time as a
lecturer for a planetarium, where I took a portable planetarium to elementary schools
and presented lectures about stars and planets. I also did private tutoring. While in
graduate school I have assisted in teaching several classes.
Lessons have I learned from my experiences as a teacher and a student:
Good teachers:
Make learning fun, even if it means doing things that seem silly
Enjoy what they are doing
Make time for their students96
Take the time necessary to prepare for lectures and lessons
Have high expectations of their students
Teach students to think for themselves
Create opportunities for students to discover things on their own
Make sure they are having a good time, if the teacher enjoys what they are
teaching, the students will be swept up by the teacher's enthusiasm.
Ask lots of questions, but don't always supply the answers
Focus on the students, not on themselves
The key to being a good teacher is having students who want to learn. Some
students come to class motivated to learn. These students need very little help from
teachers. Many students need to be motivated. A good teacher will find ways to make
students want to learn. Once students want to learn, the teacher's job is easy. The
teacher only needs to provide or direct students to resources and help the students set
goals. If a student is motivated to learn, they will teach themselves.97
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